The Treatment of Painful Diabetic Neuropathy

Gordon      Sloan; Uazman      Alam; Dinesh      Selvarajah; Solomon      Tesfaye
doi:10.2174/1573399817666210707112413
Abstract

Painful diabetic peripheral neuropathy (painful-DPN) is a highly prevalent and disabling condition, affecting up to one-third of patients with diabetes. This condition can have a profound impact resulting in a poor quality of life, disruption of employment, impaired sleep, and poor mental health with an excess of depression and anxiety. The management of painful-DPN poses a great challenge. Unfortunately, currently there are no Food and Drug Administration (USA) approved disease-modifying treatments for diabetic peripheral neuropathy (DPN) as trials of putative pathogenetic treatments have failed at phase 3 clinical trial stage. Therefore, the focus of managing painful- DPN other than improving glycaemic control and cardiovascular risk factor modification is treating symptoms. The recommended treatments based on expert international consensus for painful- DPN have remained essentially unchanged for the last decade. Both the serotonin re-uptake inhibitor (SNRI) duloxetine and α2δ ligand pregabalin have the most robust evidence for treating painful-DPN. The weak opioids (e.g. tapentadol and tramadol, both of which have an SNRI effect), tricyclic antidepressants such as amitriptyline and α2δ ligand gabapentin are also widely recommended and prescribed agents. Opioids (except tramadol and tapentadol), should be prescribed with caution in view of the lack of definitive data surrounding efficacy, concerns surrounding addiction and adverse events. Recently, emerging therapies have gained local licenses, including the α2δ ligand mirogabalin (Japan) and the high dose 8% capsaicin patch (FDA and Europe). The management of refractory painful-DPN is difficult; specialist pain services may offer off-label therapies (e.g. botulinum toxin, intravenous lidocaine and spinal cord stimulation), although there is limited clinical trial evidence supporting their use. Additionally, despite combination therapy being commonly used clinically, there is little evidence supporting this practise. There is a need for further clinical trials to assess novel therapeutic agents, optimal combination therapy and existing agents to determine which are the most effective for the treatment of painful-DPN. This article reviews the evidence for the treatment of painful-DPN, including emerging treatment strategies such as novel compounds and stratification of patients according to individual characteristics (e.g. pain phenotype, neuroimaging and genotype) to improve treatment responses.
Keywords: Painful-DPN, ligand pregabalin, ligand mirogabalin, Opioids, pathogenetic treatments, novel therapeutic agents.
[1] 
Saeedi P, Petersohn I, Salpea P, et al. Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: Results from the International Diabetes Federation Diabetes Atlas, 9th edition. Diabetes Res Clin Pract  2019; 157: 107843.
[http://dx.doi.org/10.1016/j.diabres.2019.107843] [PMID: 31518657] 
[2] 
Williams R, Karuranga S, Malanda B, et al. Global and regional estimates and projections of diabetes-related health expenditure: Results from the International Diabetes Federation Diabetes Atlas, 9th edition. Diabetes Res Clin Pract  2020; 162: 108072.
[http://dx.doi.org/10.1016/j.diabres.2020.108072] [PMID: 32061820] 
[3] 
Gregg EW, Li Y, Wang J, et al. Changes in diabetes-related complications in the United States, 1990-2010. N Engl J Med  2014; 370(16): 1514-23.
[http://dx.doi.org/10.1056/NEJMoa1310799] [PMID: 24738668] 
[4] 
Reiber GE, Vileikyte L, Boyko EJ, et al. Causal pathways for incident lower-extremity ulcers in patients with diabetes from two settings. Diabetes Care  1999; 22(1): 157-62.
[http://dx.doi.org/10.2337/diacare.22.1.157] [PMID: 10333919] 
[5] 
Vadiveloo T, Jeffcoate W, Donnan PT, et al. Amputation-free survival in 17,353 people at high risk for foot ulceration in diabetes: a national observational study. Diabetologia  2018; 61(12): 2590-7.
[http://dx.doi.org/10.1007/s00125-018-4723-y] [PMID: 30171278] 
[6] 
Rastogi A, Goyal G, Kesavan R, et al. Long term outcomes after incident diabetic foot ulcer: Multicenter large cohort prospective study (EDI-FOCUS investigators) epidemiology of diabetic foot complications study: Epidemiology of diabetic foot complications study. Diabetes Res Clin Pract  2020; 162: 108113.
[http://dx.doi.org/10.1016/j.diabres.2020.108113] [PMID: 32165163] 
[7] 
Kerr M. Foot care in diabetes: The human and financial cost. 2017. Available from: http://www.londonscn.nhs.uk/wp- content/uploads/2017/04/dia-foot-care-mtg-kerr-27042017.pdf
[8] 
Tesfaye S, Boulton AJ, Dyck PJ, et al. Diabetic neuropathies: update on definitions, diagnostic criteria, estimation of severity, and treatments. Diabetes Care  2010; 33(10): 2285-93.
[http://dx.doi.org/10.2337/dc10-1303] [PMID: 20876709] 
[9] 
Sloan G, Shillo P, Selvarajah D, et al. A new look at painful diabetic neuropathy. Diabetes Res Clin Pract  2018; 144: 177-91.
[http://dx.doi.org/10.1016/j.diabres.2018.08.020] [PMID: 30201394] 
[10] 
Tesfaye S, Selvarajah D, Gandhi R, et al. Diabetic peripheral neuropathy may not be as its name suggests: evidence from magnetic resonance imaging. Pain  2016; 157(Suppl. 1): S72-80.
[http://dx.doi.org/10.1097/j.pain.0000000000000465] [PMID: 26785159] 
[11] 
Selvarajah D, Wilkinson ID, Fang F, et al. Structural and functional abnormalities of the primary somatosensory cortex in diabetic peripheral neuropathy: A multimodal mri study. Diabetes  2019; 68(4): 796-806.
[http://dx.doi.org/10.2337/db18-0509] [PMID: 30617218] 
[12] 
Wilkinson ID, Teh K, Heiberg-Gibbons F, et al. Determinants of treatment response in painful diabetic peripheral neuropathy. A combined deep sensory phenotyping and multi-modal brain magnetic resonance imaging study. Diabetes  2020; 69(8): 1804-14.
[http://dx.doi.org/10.2337/db20-0029] [PMID: 32471808] 
[13] 
Davies M, Brophy S, Williams R, Taylor A. The prevalence, severity, and impact of painful diabetic peripheral neuropathy in type 2 diabetes. Diabetes Care  2006; 29(7): 1518-22.
[http://dx.doi.org/10.2337/dc05-2228] [PMID: 16801572] 
[14] 
Tölle T, Xu X, Sadosky AB. Painful diabetic neuropathy: a cross-sectional survey of health state impairment and treatment patterns. J Diabetes Complications  2006; 20(1): 26-33.
[http://dx.doi.org/10.1016/j.jdiacomp.2005.09.007] [PMID: 16389164] 
[15] 
Selvarajah D, Cash T, Sankar A, et al. The contributors of emotional distress in painful diabetic neuropathy. Diab Vasc Dis Res  2014; 11(4): 218-25.
[http://dx.doi.org/10.1177/1479164114522135] [PMID: 24821753] 
[16] 
Challapalli V, Tremont-Lukats IW, McNicol ED, Lau J, Carr DB. Systemic administration of local anesthetic agents to relieve neuropathic pain. Cochrane Database Syst Rev  2005; 2005(4): CD003345.
[PMID: 16235318] 
[17] 
Saarto T, Wiffen PJ. Antidepressants for neuropathic pain. Cochrane Database Syst Rev  2007; 2007(4): CD005454.
[PMID: 17943857] 
[18] 
Chalk C, Benstead TJ, Moore F. Aldose reductase inhibitors for the treatment of diabetic polyneuropathy. Cochrane Database Syst Rev  2007; 2007(4): CD004572.
[http://dx.doi.org/10.1002/14651858.CD004572.pub2] [PMID: 17943821] 
[19] 
Noble M, Treadwell JR, Tregear SJ, et al. Long-term opioid management for chronic noncancer pain. Cochrane Database Syst Rev  2010; 2010(1): CD006605.
[http://dx.doi.org/10.1002/14651858.CD006605.pub2] [PMID: 20091598] 
[20] 
Gill D, Derry S, Wiffen PJ, Moore RA. Valproic acid and sodium valproate for neuropathic pain and fibromyalgia in adults. Cochrane Database Syst Rev  2011; 2011(10): CD009183.
[PMID: 21975791] 
[21] 
Corrigan R, Derry S, Wiffen PJ, Moore RA. Clonazepam for neuropathic pain and fibromyalgia in adults. Cochrane Database Syst Rev  2012; 2012(5): CD009486.
[http://dx.doi.org/10.1002/14651858.CD009486.pub2] [PMID: 22592742] 
[22] 
Birse F, Derry S, Moore RA. Phenytoin for neuropathic pain and fibromyalgia in adults. Cochrane Database Syst Rev  2012; 2012(5): CD009485.
[http://dx.doi.org/10.1002/14651858.CD009485.pub2] [PMID: 22592741] 
[23] 
Hearn L, Derry S, Moore RA. Lacosamide for neuropathic pain and fibromyalgia in adults. Cochrane Database Syst Rev  2012; 2012(2): CD009318.
[http://dx.doi.org/10.1002/14651858.CD009318.pub2] [PMID: 22336864] 
[24] 
Derry S, Moore RA. Topical capsaicin (low concentration) for chronic neuropathic pain in adults. Cochrane Database Syst Rev  2012; 2012(9): CD010111.
[http://dx.doi.org/10.1002/14651858.CD010111] [PMID: 22972149] 
[25] 
Leucht C, Huhn M, Leucht S. Amitriptyline versus placebo for major depressive disorder. Cochrane Database Syst Rev  2012; 12(12): CD009138.
[http://dx.doi.org/10.1002/14651858.CD009138.pub2] [PMID: 23235671] 
[26] 
Chaparro LE, Wiffen PJ, Moore RA, Gilron I. Combination pharmacotherapy for the treatment of neuropathic pain in adults. Cochrane Database Syst Rev  2012; 2012(7): CD008943.
[PMID: 22786518] 
[27] 
Wiffen PJ, Derry S, Moore RA, et al. Antiepileptic drugs for neuropathic pain and fibromyalgia - an overview of Cochrane reviews. Cochrane Database Syst Rev  2013; 2013(11): CD010567.
[http://dx.doi.org/10.1002/14651858.CD010567.pub2] [PMID: 24217986] 
[28] 
Zhou M, Chen N, He L, Yang M, Zhu C, Wu F. Oxcarbazepine for neuropathic pain. Cochrane Database Syst Rev  2013; 2013(3): CD007963.
[PMID: 23543558] 
[29] 
Wiffen PJ, Derry S, Lunn MP, Moore RA. Topiramate for neuropathic pain and fibromyalgia in adults. Cochrane Database Syst Rev  2013; 2013(8): CD008314.
[http://dx.doi.org/10.1002/14651858.CD008314.pub2] [PMID: 23996081] 
[30] 
Wiffen PJ, Derry S, Moore RA. Lamotrigine for chronic neuropathic pain and fibromyalgia in adults. Cochrane Database Syst Rev  2013; 2013(12): CD006044.
[http://dx.doi.org/10.1002/14651858.CD006044.pub4] [PMID: 24297457] 
[31] 
McNicol ED, Midbari A, Eisenberg E. Opioids for neuropathic pain. Cochrane Database Syst Rev  2013; 2013(8): CD006146.
[PMID: 23986501] 
[32] 
Gaskell H, Moore RA, Derry S, Stannard C. Oxycodone for neuropathic pain and fibromyalgia in adults. Cochrane Database Syst Rev  2014; 2014(6): CD010692.
[http://dx.doi.org/10.1002/14651858.CD010692.pub2] [PMID: 24956205] 
[33] 
Wiffen PJ, Derry S, Moore RA, Kalso EA. Carbamazepine for chronic neuropathic pain and fibromyalgia in adults. Cochrane Database Syst Rev  2014; 2014(4): CD005451.
[http://dx.doi.org/10.1002/14651858.CD005451.pub3] [PMID: 24719027] 
[34] 
Wiffen PJ, Derry S, Moore RA, Lunn MP. Levetiracetam for neuropathic pain in adults. Cochrane Database Syst Rev  2014; 2014(7): CD010943.
[PMID: 25000215] 
[35] 
Derry S, Wiffen PJ, Moore RA, Quinlan J. Topical lidocaine for neuropathic pain in adults. Cochrane Database Syst Rev  2014; 2014(7): CD010958.
[http://dx.doi.org/10.1002/14651858.CD010958] [PMID: 25058164] 
[36] 
Hearn L, Derry S, Phillips T, Moore RA, Wiffen PJ. Imipramine for neuropathic pain in adults. Cochrane Database Syst Rev  2014; 2014(5): CD010769.
[PMID: 24838845] 
[37] 
Hearn L, Moore RA, Derry S, Wiffen PJ, Phillips T. Desipramine for neuropathic pain in adults. Cochrane Database Syst Rev  2014; 2014(9): CD011003.
[PMID: 25246131] 
[38] 
Lunn MP, Hughes RA, Wiffen PJ. Duloxetine for treating painful neuropathy, chronic pain or fibromyalgia. Cochrane Database Syst Rev  2014; 2014(1): CD007115.
[http://dx.doi.org/10.1002/14651858.CD007115.pub3] [PMID: 24385423] 
[39] 
Fullerton B, Jeitler K, Seitz M, Horvath K, Berghold A, Siebenhofer A. Intensive glucose control versus conventional glucose control for type 1 diabetes mellitus. Cochrane Database Syst Rev  2014; 2014(2): CD009122.
[http://dx.doi.org/10.1002/14651858.CD009122.pub2] [PMID: 24526393] 
[40] 
Moore RA, Chi CC, Wiffen PJ, Derry S, Rice AS. Oral nonsteroidal anti-inflammatory drugs for neuropathic pain. Cochrane Database Syst Rev  2015; 2015(10): CD010902.
[http://dx.doi.org/10.1002/14651858.CD010902.pub2] [PMID: 26436601] 
[41] 
Wrzosek A, Woron J, Dobrogowski J, Jakowicka-Wordliczek J, Wordliczek J. Topical clonidine for neuropathic pain. Cochrane Database Syst Rev  2015; 8(8): CD010967.
[PMID: 26329307] 
[42] 
Cording M, Derry S, Phillips T, Moore RA, Wiffen PJ. Milnacipran for pain in fibromyalgia in adults. Cochrane Database Syst Rev  2015; 2015(10): CD008244.
[http://dx.doi.org/10.1002/14651858.CD008244.pub3] [PMID: 26482422] 
[43] 
Moore RA, Derry S, Aldington D, Cole P, Wiffen PJ. Amitriptyline for neuropathic pain in adults. Cochrane Database Syst Rev  2015; 2015(7): CD008242.
[PMID: 26146793] 
[44] 
Gallagher HC, Gallagher RM, Butler M, Buggy DJ, Henman MC. Venlafaxine for neuropathic pain in adults. Cochrane Database Syst Rev  2015; 2015(8): CD011091.
[PMID: 26298465] 
[45] 
Derry S, Wiffen PJ, Aldington D, Moore RA. Nortriptyline for neuropathic pain in adults. Cochrane Database Syst Rev  2015; 1(1): CD011209.
[PMID: 25569864] 
[46] 
Gaskell H, Derry S, Stannard C, Moore RA. Oxycodone for neuropathic pain in adults. Cochrane Database Syst Rev  2016; 7(7): CD010692.
[PMID: 27465317] 
[47] 
Wiffen PJ, Knaggs R, Derry S, Cole P, Phillips T, Moore RA. Paracetamol (acetaminophen) with or without codeine or dihydrocodeine for neuropathic pain in adults. Cochrane Database Syst Rev  2016; 12(12): CD012227.
[http://dx.doi.org/10.1002/14651858.CD012227] [PMID: 28027389] 
[48] 
Cooper TE, Chen J, Wiffen PJ, et al. Morphine for chronic neuropathic pain in adults. Cochrane Database Syst Rev  2017; 5(5): CD011669.
[http://dx.doi.org/10.1002/14651858.CD011669.pub2] [PMID: 28530786] 
[49] 
Duehmke RM, Derry S, Wiffen PJ, Bell RF, Aldington D, Moore RA. Tramadol for neuropathic pain in adults. Cochrane Database Syst Rev  2017; 6(6): CD003726.
[PMID: 28616956] 
[50] 
Zhou M, Chen N, He L, Yang M, Zhu C, Wu F. Oxcarbazepine for neuropathic pain. Cochrane Database Syst Rev  2017; 12(12): CD007963.
[PMID: 29199767] 
[51] 
Derry S, Wiffen PJ, Kalso EA, et al. Topical analgesics for acute and chronic pain in adults - an overview of Cochrane Reviews. Cochrane Database Syst Rev  2017; 5(5): CD008609.
[http://dx.doi.org/10.1002/14651858.CD008609.pub2] [PMID: 28497473] 
[52] 
Derry S, Rice AS, Cole P, Tan T, Moore RA. Topical capsaicin (high concentration) for chronic neuropathic pain in adults. Cochrane Database Syst Rev  2017; 1(1): CD007393.
[http://dx.doi.org/10.1002/14651858.CD007393.pub4] [PMID: 28085183] 
[53] 
Wiffen PJ, Derry S, Bell RF, et al. Gabapentin for chronic neuropathic pain in adults. Cochrane Database Syst Rev  2017; 6(6): CD007938.
[http://dx.doi.org/10.1002/14651858.CD007938.pub4] [PMID: 28597471] 
[54] 
Mücke M, Phillips T, Radbruch L, Petzke F, Häuser W. Cannabis-based medicines for chronic neuropathic pain in adults. Cochrane Database Syst Rev  2018; 3(3): CD012182.
[http://dx.doi.org/10.1002/14651858.CD012182.pub2] [PMID: 29513392] 
[55] 
Rolim LC, da Silva EM, Flumignan RL, Abreu MM, Dib SA. Acetyl-L-carnitine for the treatment of diabetic peripheral neuropathy. Cochrane Database Syst Rev  2019; 6(6): CD011265.
[http://dx.doi.org/10.1002/14651858.CD011265.pub2] [PMID: 31201734] 
[56] 
Challapalli V, Tremont-Lukats IW, McNicol ED, Lau J, Carr DB. Systemic administration of local anesthetic agents to relieve neuropathic pain. Cochrane Database Syst Rev  2019; 2019(10)
[PMID: 31684682] 
[57] 
Derry S, Bell RF, Straube S, Wiffen PJ, Aldington D, Moore RA. Pregabalin for neuropathic pain in adults. Cochrane Database Syst Rev  2019; 1(1): CD007076.
[PMID: 30673120] 
[58] 
 (NICE) NIoCE. Neuropathic pain in adults: Pharmacological management in non-specialist settings. NICE 2018.
[59] 
Attal N, Cruccu G, Baron R, et al. EFNS guidelines on the pharmacological treatment of neuropathic pain: 2010 revision. Eur J Neurol  2010; 17(9): 1113-e88.
[http://dx.doi.org/10.1111/j.1468-1331.2010.02999.x] [PMID: 20402746] 
[60] 
Finnerup NB, Attal N, Haroutounian S, et al. Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis. Lancet Neurol  2015; 14(2): 162-73.
[http://dx.doi.org/10.1016/S1474-4422(14)70251-0] [PMID: 25575710] 
[61] 
Pop-Busui R, Boulton AJ, Feldman EL, et al. Diabetic neuropathy: A position statement by the american diabetes association. Diabetes Care  2017; 40(1): 136-54.
[http://dx.doi.org/10.2337/dc16-2042] [PMID: 27999003] 
[62] 
Handelsman Y, Henry RR, Bloomgarden ZT, et al. American association of clinical endocrinologists and american college of endocrinology position statement on the association of sglt-2 inhibitors and diabetic ketoacidosis. Endocr Pract  2016; 22(6): 753-62.
[http://dx.doi.org/10.4158/EP161292.PS] [PMID: 27082665] 
[63] 
Bril V, England J, Franklin GM, et al. Evidence-based guideline: Treatment of painful diabetic neuropathy: Report of the american academy of neurology, the american association of neuromuscular and electrodiagnostic medicine, and the american academy of physical medicine and rehabilitation. Neurology  2011; 76(20): 1758-65.
[http://dx.doi.org/10.1212/WNL.0b013e3182166ebe] [PMID: 21482920] 
[64] 
Ziegler D, Papanas N, Vinik AI, Shaw JE. Epidemiology of polyneuropathy in diabetes and prediabetes. Handb Clin Neurol  2014; 126: 3-22.
[http://dx.doi.org/10.1016/B978-0-444-53480-4.00001-1] [PMID: 25410210] 
[65] 
Hicks CW, Selvin E. Epidemiology of peripheral neuropathy and lower extremity disease in diabetes. Curr Diab Rep  2019; 19(10): 86.
[http://dx.doi.org/10.1007/s11892-019-1212-8] [PMID: 31456118] 
[66] 
Andersen ST, Witte DR, Dalsgaard EM, et al. Risk factors for incident diabetic polyneuropathy in a cohort with screen-detected type 2 diabetes followed for 13 years: Addition-denmark. Diabetes Care  2018; 41(5): 1068-75.
[http://dx.doi.org/10.2337/dc17-2062] [PMID: 29487078] 
[67] 
Mizokami-Stout KR, Li Z, Foster NC, et al. The contemporary prevalence of diabetic neuropathy in type 1 diabetes: Findings from the t1d exchange. Diabetes Care  2020; 43(4): 806-12.
[http://dx.doi.org/10.2337/dc19-1583] [PMID: 32029635] 
[68] 
Partanen J, Niskanen L, Lehtinen J, Mervaala E, Siitonen O, Uusitupa M. Natural history of peripheral neuropathy in patients with non-insulin-dependent diabetes mellitus. N Engl J Med  1995; 333(2): 89-94.
[http://dx.doi.org/10.1056/NEJM199507133330203] [PMID: 7777034] 
[69] 
Martin CL, Albers JW, Pop-Busui R, Group DER. Neuropathy and related findings in the diabetes control and complications trial/epidemiology of diabetes interventions and complications study. Diabetes Care  2014; 37(1): 31-8.
[http://dx.doi.org/10.2337/dc13-2114] [PMID: 24356595] 
[70] 
Dyck PJ, Kratz KM, Karnes JL, et al. The prevalence by staged severity of various types of diabetic neuropathy, retinopathy, and nephropathy in a population-based cohort: the Rochester Diabetic Neuropathy Study. Neurology  1993; 43(4): 817-24.
[http://dx.doi.org/10.1212/WNL.43.4.817] [PMID: 8469345] 
[71] 
Tesfaye S, Chaturvedi N, Eaton SE, et al. Vascular risk factors and diabetic neuropathy. N Engl J Med  2005; 352(4): 341-50.
[http://dx.doi.org/10.1056/NEJMoa032782] [PMID: 15673800] 
[72] 
Braffett BH, Gubitosi-Klug RA, Albers JW, et al. Risk factors for diabetic peripheral neuropathy and cardiovascular autonomic neuropathy in the diabetes control and complications trial/epidemiology of diabetes interventions and complications (dcct/edic) study. Diabetes  2020; 69(5): 1000-10.
[http://dx.doi.org/10.2337/db19-1046] [PMID: 32051148] 
[73] 
Alleman CJ, Westerhout KY, Hensen M, et al. Humanistic and economic burden of painful diabetic peripheral neuropathy in Europe: A review of the literature. Diabetes Res Clin Pract  2015; 109(2): 215-25.
[http://dx.doi.org/10.1016/j.diabres.2015.04.031] [PMID: 26008721] 
[74] 
Abbott CA, Malik RA, van Ross ER, Kulkarni J, Boulton AJ. Prevalence and characteristics of painful diabetic neuropathy in a large community-based diabetic population in the U.K. Diabetes Care  2011; 34(10): 2220-4.
[http://dx.doi.org/10.2337/dc11-1108] [PMID: 21852677] 
[75] 
Stino AM, Smith AG. Peripheral neuropathy in prediabetes and the metabolic syndrome. J Diabetes Investig  2017; 8(5): 646-55.
[http://dx.doi.org/10.1111/jdi.12650] [PMID: 28267267] 
[76] 
Ziegler D, Rathmann W, Dickhaus T, Meisinger C, Mielck A, Group KS. Neuropathic pain in diabetes, prediabetes and normal glucose tolerance: the MONICA/KORA Augsburg Surveys S2 and S3. Pain Med  2009; 10(2): 393-400.
[http://dx.doi.org/10.1111/j.1526-4637.2008.00555.x] [PMID: 19207236] 
[77] 
Shillo P, Sloan G, Greig M, et al. Painful and painless diabetic neuropathies: What is the difference? Curr Diab Rep  2019; 19(6): 32.
[http://dx.doi.org/10.1007/s11892-019-1150-5] [PMID: 31065863] 
[78] 
Meng W, Deshmukh HA, Donnelly LA, et al. A genome-wide association study provides evidence of sex-specific involvement of chr1p35.1 (zscan20-tlr12p) and chr8p23.1 (hmgb1p46) with diabetic neuropathic pain. EBioMedicine  2015; 2(10): 1386-93.
[http://dx.doi.org/10.1016/j.ebiom.2015.08.001] [PMID: 26629533] 
[79] 
Meng W, Deshmukh HA, van Zuydam NR, et al. A genome-wide association study suggests an association of Chr8p21.3 (GFRA2) with diabetic neuropathic pain. Eur J Pain  2015; 19(3): 392-9.
[http://dx.doi.org/10.1002/ejp.560] [PMID: 24974787] 
[80] 
Blesneac I, Themistocleous AC, Fratter C, et al. Rare Nav1.7 variants associated with painful diabetic peripheral neuropathy. Pain  2018; 159(3): 469-80.
[PMID: 29176367] 
[81] 
Binns-Hall O, Selvarajah D, Sanger D, Walker J, Scott A, Tesfaye S. One-stop microvascular screening service: an effective model for the early detection of diabetic peripheral neuropathy and the high-risk foot. Diabet Med  2018; 35(7): 887-94.
[http://dx.doi.org/10.1111/dme.13630] [PMID: 29608799] 
[82] 
Daousi C, MacFarlane IA, Woodward A, Nurmikko TJ, Bundred PE, Benbow SJ. Chronic painful peripheral neuropathy in an urban community: a controlled comparison of people with and without diabetes. Diabet Med  2004; 21(9): 976-82.
[http://dx.doi.org/10.1111/j.1464-5491.2004.01271.x] [PMID: 15317601] 
[83] 
Sadosky A, Mardekian J, Parsons B, Hopps M, Bienen EJ, Markman J. Healthcare utilization and costs in diabetes relative to the clinical spectrum of painful diabetic peripheral neuropathy. J Diabetes Complications  2015; 29(2): 212-7.
[http://dx.doi.org/10.1016/j.jdiacomp.2014.10.013] [PMID: 25498300] 
[84] 
Tracey I, Mantyh PW. The cerebral signature and its modulation for pain perception. Neuron  2007; 55(3): 377-91.
[http://dx.doi.org/10.1016/j.neuron.2007.07.012] [PMID: 17678852] 
[85] 
IASP. IASP Taxonomy  Available from: https://www.iasp-pain.org/Taxonomy?navItemNumber=5762012
[86] 
Galer BS, Gianas A, Jensen MP. Painful diabetic polyneuropathy: epidemiology, pain description, and quality of life. Diabetes Res Clin Pract  2000; 47(2): 123-8.
[http://dx.doi.org/10.1016/S0168-8227(99)00112-6] [PMID: 10670912] 
[87] 
Gylfadottir SS, Christensen DH, Nicolaisen SK, et al. Diabetic polyneuropathy and pain, prevalence, and patient characteristics: a cross-sectional questionnaire study of 5,514 patients with recently diagnosed type 2 diabetes. Pain  2020; 161(3): 574-83.
[http://dx.doi.org/10.1097/j.pain.0000000000001744] [PMID: 31693539] 
[88] 
Themistocleous AC, Ramirez JD, Shillo PR, et al. The Pain in Neuropathy Study (PiNS): a cross-sectional observational study determining the somatosensory phenotype of painful and painless diabetic neuropathy. Pain  2016; 157(5): 1132-45.
[http://dx.doi.org/10.1097/j.pain.0000000000000491] [PMID: 27088890] 
[89] 
Raputova J, Srotova I, Vlckova E, et al. Sensory phenotype and risk factors for painful diabetic neuropathy: a cross-sectional observational study. Pain  2017; 158(12): 2340-53.
[http://dx.doi.org/10.1097/j.pain.0000000000001034] [PMID: 28858986] 
[90] 
Gore M, Brandenburg NA, Dukes E, Hoffman DL, Tai KS, Stacey B. Pain severity in diabetic peripheral neuropathy is associated with patient functioning, symptom levels of anxiety and depression, and sleep. J Pain Symptom Manage  2005; 30(4): 374-85.
[http://dx.doi.org/10.1016/j.jpainsymman.2005.04.009] [PMID: 16256902] 
[91] 
Boulton AJ, Armstrong WD, Scarpello JH, Ward JD. The natural history of painful diabetic neuropathy--a 4-year study. Postgrad Med J  1983; 59(695): 556-9.
[http://dx.doi.org/10.1136/pgmj.59.695.556] [PMID: 6634554] 
[92] 
Daousi C, Benbow SJ, Woodward A, MacFarlane IA. The natural history of chronic painful peripheral neuropathy in a community diabetes population. Diabet Med  2006; 23(9): 1021-4.
[http://dx.doi.org/10.1111/j.1464-5491.2006.01904.x] [PMID: 16922710] 
[93] 
Lapin BR, Pantalone KM, Milinovich A, et al. Pain in patients with type 2 diabetes-related polyneuropathy is associated with vascular events and mortality. J Clin Endocrinol Metab  2020; 105(9): dgaa394.
[http://dx.doi.org/10.1210/clinem/dgaa394] [PMID: 32575118] 
[94] 
Feldman EL, Stevens MJ, Thomas PK, Brown MB, Canal N, Greene DA. A practical two-step quantitative clinical and electrophysiological assessment for the diagnosis and staging of diabetic neuropathy. Diabetes Care  1994; 17(11): 1281-9.
[http://dx.doi.org/10.2337/diacare.17.11.1281] [PMID: 7821168] 
[95] 
Bril V, Perkins BA. Validation of the toronto clinical scoring system for diabetic polyneuropathy. Diabetes Care  2002; 25(11): 2048-52.
[http://dx.doi.org/10.2337/diacare.25.11.2048] [PMID: 12401755] 
[96] 
Young MJ, Boulton AJ, MacLeod AF, Williams DR, Sonksen PH. A multicentre study of the prevalence of diabetic peripheral neuropathy in the United Kingdom hospital clinic population. Diabetologia  1993; 36(2): 150-4.
[http://dx.doi.org/10.1007/BF00400697] [PMID: 8458529] 
[97] 
Dyck PJ, Davies JL, Litchy WJ, O’Brien PC. Longitudinal assessment of diabetic polyneuropathy using a composite score in the Rochester Diabetic Neuropathy Study cohort. Neurology  1997; 49(1): 229-39.
[http://dx.doi.org/10.1212/WNL.49.1.229] [PMID: 9222195] 
[98] 
Spallone V, Morganti R, D’Amato C, Greco C, Cacciotti L, Marfia GA. Validation of DN4 as a screening tool for neuropathic pain in painful diabetic polyneuropathy. Diabet Med  2012; 29(5): 578-85.
[http://dx.doi.org/10.1111/j.1464-5491.2011.03500.x] [PMID: 22023377] 
[99] 
Bennett M. The LANSS Pain Scale: the Leeds assessment of neuropathic symptoms and signs. Pain  2001; 92(1-2): 147-57.
[http://dx.doi.org/10.1016/S0304-3959(00)00482-6] [PMID: 11323136] 
[100] 
Freynhagen R, Baron R, Gockel U, Tölle TR. painDETECT: a new screening questionnaire to identify neuropathic components in patients with back pain. Curr Med Res Opin  2006; 22(10): 1911-20.
[http://dx.doi.org/10.1185/030079906X132488] [PMID: 17022849] 
[101] 
Bastyr EJ III, Price KL, Bril V, Group MS. Development and validity testing of the neuropathy total symptom score-6: questionnaire for the study of sensory symptoms of diabetic peripheral neuropathy. Clin Ther  2005; 27(8): 1278-94.
[http://dx.doi.org/10.1016/j.clinthera.2005.08.002] [PMID: 16199253] 
[102] 
Dyck PJ. Detection, characterization, and staging of polyneuropathy: assessed in diabetics. Muscle Nerve  1988; 11(1): 21-32.
[http://dx.doi.org/10.1002/mus.880110106] [PMID: 3277049] 
[103] 
Meijer JW, Bosma E, Lefrandt JD, et al. Clinical diagnosis of diabetic polyneuropathy with the diabetic neuropathy symptom and diabetic neuropathy examination scores. Diabetes Care  2003; 26(3): 697-701.
[http://dx.doi.org/10.2337/diacare.26.3.697] [PMID: 12610024] 
[104] 
Vileikyte L, Peyrot M, Bundy C, et al. The development and validation of a neuropathy- and foot ulcer-specific quality of life instrument. Diabetes Care  2003; 26(9): 2549-55.
[http://dx.doi.org/10.2337/diacare.26.9.2549] [PMID: 12941717] 
[105] 
Vinik EJ, Hayes RP, Oglesby A, et al. The development and validation of the Norfolk QOL-DN, a new measure of patients’ perception of the effects of diabetes and diabetic neuropathy. Diabetes Technol Ther  2005; 7(3): 497-508.
[http://dx.doi.org/10.1089/dia.2005.7.497] [PMID: 15929681] 
[106] 
Tesfaye S, Boulton AJ, Dickenson AH. Mechanisms and management of diabetic painful distal symmetrical polyneuropathy. Diabetes Care  2013; 36(9): 2456-65.
[http://dx.doi.org/10.2337/dc12-1964] [PMID: 23970715] 
[107] 
Yorek MA. Alternatives to the streptozotocin-diabetic rodent. Int Rev Neurobiol  2016; 127: 89-112.
[http://dx.doi.org/10.1016/bs.irn.2016.03.002] [PMID: 27133146] 
[108] 
Feldman EL, Callaghan BC, Pop-Busui R, et al. Diabetic neuropathy. Nat Rev Dis Primers  2019; 5(1): 41.
[http://dx.doi.org/10.1038/s41572-019-0092-1] [PMID: 31197153] 
[109] 
Feldman EL, Nave KA, Jensen TS, Bennett DLH. New horizons in diabetic neuropathy: Mechanisms, bioenergetics, and pain. Neuron  2017; 93(6): 1296-313.
[http://dx.doi.org/10.1016/j.neuron.2017.02.005] [PMID: 28334605] 
[110] 
Colloca L, Ludman T, Bouhassira D, et al. Neuropathic pain. Nat Rev Dis Primers  2017; 3: 17002.
[http://dx.doi.org/10.1038/nrdp.2017.2] [PMID: 28205574] 
[111] 
Quattrini C, Tavakoli M, Jeziorska M, et al. Surrogate markers of small fiber damage in human diabetic neuropathy. Diabetes  2007; 56(8): 2148-54.
[http://dx.doi.org/10.2337/db07-0285] [PMID: 17513704] 
[112] 
Marshall AG, Lee-Kubli C, Azmi S, et al. Spinal disinhibition in experimental and clinical painful diabetic neuropathy. Diabetes  2017; 66(5): 1380-90.
[http://dx.doi.org/10.2337/db16-1181] [PMID: 28202580] 
[113] 
Kalteniece A, Ferdousi M, Petropoulos I, et al. Greater corneal nerve loss at the inferior whorl is related to the presence of diabetic neuropathy and painful diabetic neuropathy. Sci Rep  2018; 8(1): 3283.
[http://dx.doi.org/10.1038/s41598-018-21643-z] [PMID: 29459766] 
[114] 
Kalteniece A, Ferdousi M, Azmi S, et al. Corneal confocal microscopy detects small nerve fibre damage in patients with painful diabetic neuropathy. Sci Rep  2020; 10(1): 3371.
[http://dx.doi.org/10.1038/s41598-020-60422-7] [PMID: 32099076] 
[115] 
Bönhof GJ, Strom A, Püttgen S, et al. Patterns of cutaneous nerve fibre loss and regeneration in type 2 diabetes with painful and painless polyneuropathy. Diabetologia  2017; 60(12): 2495-503.
[http://dx.doi.org/10.1007/s00125-017-4438-5] [PMID: 28914336] 
[116] 
Cheng HT, Dauch JR, Porzio MT, et al. Increased axonal regeneration and swellings in intraepidermal nerve fibers characterize painful phenotypes of diabetic neuropathy. J Pain  2013; 14(9): 941-7.
[http://dx.doi.org/10.1016/j.jpain.2013.03.005] [PMID: 23685187] 
[117] 
Galosi E, La Cesa S, Di Stefano G, et al. A pain in the skin. Regenerating nerve sprouts are distinctly associated with ongoing burning pain in patients with diabetes. Eur J Pain  2018; 22(10): 1727-34.
[http://dx.doi.org/10.1002/ejp.1259] [PMID: 29885017] 
[118] 
Scheytt S, Riediger N, Braunsdorf S, Sommer C, Üçeyler N. Increased gene expression of growth associated protein-43 in skin of patients with early-stage peripheral neuropathies. J Neurol Sci  2015; 355(1-2): 131-7.
[http://dx.doi.org/10.1016/j.jns.2015.05.044] [PMID: 26071889] 
[119] 
Cheung A, Podgorny P, Martinez JA, Chan C, Toth C. Epidermal axonal swellings in painful and painless diabetic peripheral neuropathy. Muscle Nerve  2015; 51(4): 505-13.
[http://dx.doi.org/10.1002/mus.24351] [PMID: 25130671] 
[120] 
Anand P, Bley K. Topical capsaicin for pain management: therapeutic potential and mechanisms of action of the new high-concentration capsaicin 8% patch. Br J Anaesth  2011; 107(4): 490-502.
[http://dx.doi.org/10.1093/bja/aer260] [PMID: 21852280] 
[121] 
Baron R, Binder A, Wasner G. Neuropathic pain: diagnosis, pathophysiological mechanisms, and treatment. Lancet Neurol  2010; 9(8): 807-19.
[http://dx.doi.org/10.1016/S1474-4422(10)70143-5] [PMID: 20650402] 
[122] 
Haroutounian S, Nikolajsen L, Bendtsen TF, et al. Primary afferent input critical for maintaining spontaneous pain in peripheral neuropathy. Pain  2014; 155(7): 1272-9.
[http://dx.doi.org/10.1016/j.pain.2014.03.022] [PMID: 24704366] 
[123] 
Ochoa JL, Campero M, Serra J, Bostock H. Hyperexcitable polymodal and insensitive nociceptors in painful human neuropathy. Muscle Nerve  2005; 32(4): 459-72.
[http://dx.doi.org/10.1002/mus.20367] [PMID: 15973653] 
[124] 
Serra J, Bostock H, Solà R, et al. Microneurographic identification of spontaneous activity in C-nociceptors in neuropathic pain states in humans and rats. Pain  2012; 153(1): 42-55.
[http://dx.doi.org/10.1016/j.pain.2011.08.015] [PMID: 21993185] 
[125] 
Bennett DL, Clark AJ, Huang J, Waxman SG, Dib-Hajj SD. The role of voltage-gated sodium channels in pain signaling. Physiol Rev  2019; 99(2): 1079-151.
[http://dx.doi.org/10.1152/physrev.00052.2017] [PMID: 30672368] 
[126] 
Bennett DL, Woods CG. Painful and painless channelopathies. Lancet Neurol  2014; 13(6): 587-99.
[http://dx.doi.org/10.1016/S1474-4422(14)70024-9] [PMID: 24813307] 
[127] 
Faber CG, Hoeijmakers JG, Ahn HS, et al. Gain of function Naν1.7 mutations in idiopathic small fiber neuropathy. Ann Neurol  2012; 71(1): 26-39.
[http://dx.doi.org/10.1002/ana.22485] [PMID: 21698661] 
[128] 
Faber CG, Lauria G, Merkies IS, et al. Gain-of-function Nav1.8 mutations in painful neuropathy. Proc Natl Acad Sci USA  2012; 109(47): 19444-9.
[http://dx.doi.org/10.1073/pnas.1216080109] [PMID: 23115331] 
[129] 
Huang J, Han C, Estacion M, et al. Gain-of-function mutations in sodium channel Na(v)1.9 in painful neuropathy. Brain  2014; 137(Pt 6): 1627-42.
[http://dx.doi.org/10.1093/brain/awu079] [PMID: 24776970] 
[130] 
Bierhaus A, Fleming T, Stoyanov S, et al. Methylglyoxal modification of Nav1.8 facilitates nociceptive neuron firing and causes hyperalgesia in diabetic neuropathy. Nat Med  2012; 18(6): 926-33.
[http://dx.doi.org/10.1038/nm.2750] [PMID: 22581285] 
[131] 
Hansen CS, Jensen TM, Jensen JS, et al. The role of serum methylglyoxal on diabetic peripheral and cardiovascular autonomic neuropathy: the ADDITION Denmark study. Diabet Med  2015; 32(6): 778-85.
[http://dx.doi.org/10.1111/dme.12753] [PMID: 25761542] 
[132] 
Du X, Gamper N. Potassium channels in peripheral pain pathways: expression, function and therapeutic potential. Curr Neuropharmacol  2013; 11(6): 621-40.
[http://dx.doi.org/10.2174/1570159X113119990042] [PMID: 24396338] 
[133] 
Djouhri L, Malki MI, Zeidan A, Nagi K, Smith T. Activation of Kv7 channels with the anticonvulsant retigabine alleviates neuropathic pain behaviour in the streptozotocin rat model of diabetic neuropathy. J Drug Target  2019; 27(10): 1118-26.
[http://dx.doi.org/10.1080/1061186X.2019.1608552] [PMID: 30995134] 
[134] 
Waxman SG, Zamponi GW. Regulating excitability of peripheral afferents: emerging ion channel targets. Nat Neurosci  2014; 17(2): 153-63.
[http://dx.doi.org/10.1038/nn.3602] [PMID: 24473263] 
[135] 
Zamponi GW, Lewis RJ, Todorovic SM, Arneric SP, Snutch TP. Role of voltage-gated calcium channels in ascending pain pathways. Brain Res Brain Res Rev  2009; 60(1): 84-9.
[http://dx.doi.org/10.1016/j.brainresrev.2008.12.021] [PMID: 19162069] 
[136] 
Saegusa H, Kurihara T, Zong S, et al. Suppression of inflammatory and neuropathic pain symptoms in mice lacking the N-type Ca2+ channel. EMBO J  2001; 20(10): 2349-56.
[http://dx.doi.org/10.1093/emboj/20.10.2349] [PMID: 11350923] 
[137] 
Doupis J, Lyons TE, Wu S, Gnardellis C, Dinh T, Veves A. Microvascular reactivity and inflammatory cytokines in painful and painless peripheral diabetic neuropathy. J Clin Endocrinol Metab  2009; 94(6): 2157-63.
[http://dx.doi.org/10.1210/jc.2008-2385] [PMID: 19276232] 
[138] 
Herder C, Kannenberg JM, Huth C, et al. Proinflammatory cytokines predict the incidence and progression of distal sensorimotor polyneuropathy: KORA F4/FF4 study. Diabetes Care  2017; 40(4): 569-76.
[http://dx.doi.org/10.2337/dc16-2259] [PMID: 28174259] 
[139] 
Tesfaye S, Malik R, Harris N, et al. Arterio-venous shunting and proliferating new vessels in acute painful neuropathy of rapid glycaemic control (insulin neuritis). Diabetologia  1996; 39(3): 329-35.
[http://dx.doi.org/10.1007/BF00418349] [PMID: 8721779] 
[140] 
Eaton SE, Harris ND, Ibrahim S, et al. Increased sural nerve epineurial blood flow in human subjects with painful diabetic neuropathy. Diabetologia  2003; 46(7): 934-9.
[http://dx.doi.org/10.1007/s00125-003-1127-3] [PMID: 12819899] 
[141] 
Quattrini C, Harris ND, Malik RA, Tesfaye S. Impaired skin microvascular reactivity in painful diabetic neuropathy. Diabetes Care  2007; 30(3): 655-9.
[http://dx.doi.org/10.2337/dc06-2154] [PMID: 17327336] 
[142] 
Shillo P, Selvarajah D, Greig M, et al. Nerve and vascular biomarkers in skin biopsies differentiate painful from painless advanced diabetic peripheral neuropathy. Diabet Med  2017; 2: 34.
[143] 
Gibbons CH, Freeman R. Treatment-induced neuropathy of diabetes: an acute, iatrogenic complication of diabetes. Brain  2015; 138(Pt 1): 43-52.
[http://dx.doi.org/10.1093/brain/awu307] [PMID: 25392197] 
[144] 
D’Mello R, Dickenson AH. Spinal cord mechanisms of pain. Br J Anaesth  2008; 101(1): 8-16.
[http://dx.doi.org/10.1093/bja/aen088] [PMID: 18417503] 
[145] 
Jolivalt CG, Lee CA, Ramos KM, Calcutt NA. Allodynia and hyperalgesia in diabetic rats are mediated by GABA and depletion of spinal potassium-chloride co-transporters. Pain  2008; 140(1): 48-57.
[http://dx.doi.org/10.1016/j.pain.2008.07.005] [PMID: 18755547] 
[146] 
Segerdahl AR, Themistocleous AC, Fido D, Bennett DL, Tracey I. A brain-based pain facilitation mechanism contributes to painful diabetic polyneuropathy. Brain  2018; 141(2): 357-64.
[http://dx.doi.org/10.1093/brain/awx337] [PMID: 29346515] 
[147] 
Zhou YQ, Liu DQ, Chen SP, et al. Minocycline as a promising therapeutic strategy for chronic pain. Pharmacol Res  2018; 134: 305-10.
[http://dx.doi.org/10.1016/j.phrs.2018.07.002] [PMID: 30042091] 
[148] 
Apkarian AV, Bushnell MC, Treede RD, Zubieta JK. Human brain mechanisms of pain perception and regulation in health and disease. Eur J Pain  2005; 9(4): 463-84.
[http://dx.doi.org/10.1016/j.ejpain.2004.11.001] [PMID: 15979027] 
[149] 
Tracey I. Imaging pain. Br J Anaesth  2008; 101(1): 32-9.
[http://dx.doi.org/10.1093/bja/aen102] [PMID: 18556697] 
[150] 
Rosenberger DC, Blechschmidt V, Timmerman H, Wolff A, Treede RD. Challenges of neuropathic pain: focus on diabetic neuropathy. J Neural Transm (Vienna)  2020; 127(4): 589-624.
[http://dx.doi.org/10.1007/s00702-020-02145-7] [PMID: 32036431] 
[151] 
Selvarajah D, Wilkinson ID, Gandhi R, Griffiths PD, Tesfaye S. Microvascular perfusion abnormalities of the Thalamus in painful but not painless diabetic polyneuropathy: a clue to the pathogenesis of pain in type 1 diabetes. Diabetes Care  2011; 34(3): 718-20.
[http://dx.doi.org/10.2337/dc10-1550] [PMID: 21282344] 
[152] 
Watanabe K, Hirano S, Kojima K, et al. Altered cerebral blood flow in the anterior cingulate cortex is associated with neuropathic pain. J Neurol Neurosurg Psychiatry  2018; 89(10): 1082-7.
[http://dx.doi.org/10.1136/jnnp-2017-316601] [PMID: 29627772] 
[153] 
Cauda F, Sacco K, D’Agata F, et al. Low-frequency BOLD fluctuations demonstrate altered thalamocortical connectivity in diabetic neuropathic pain. BMC Neurosci  2009; 10: 138.
[http://dx.doi.org/10.1186/1471-2202-10-138] [PMID: 19941658] 
[154] 
Petrou M, Pop-Busui R, Foerster BR, et al. Altered excitation-inhibition balance in the brain of patients with diabetic neuropathy. Acad Radiol  2012; 19(5): 607-12.
[http://dx.doi.org/10.1016/j.acra.2012.02.004] [PMID: 22463961] 
[155] 
Handelsman Y, Bloomgarden ZT, Grunberger G, et al. American association of clinical endocrinologists and american college of endocrinology - clinical practice guidelines for developing a diabetes mellitus comprehensive care plan - 2015. Endocr Pract  2015; 21(Suppl. 1): 1-87.
[http://dx.doi.org/10.4158/EP15672.GLSUPPL] [PMID: 25869408] 
[156] 
Azmi S, Alam U, Burgess J, Malik RA. State-of-the-art pharmacotherapy for diabetic neuropathy. Expert Opin Pharmacother  2021; 22(1): 55-68.
[http://dx.doi.org/10.1080/14656566.2020.1812578] [PMID: 32866410] 
[157] 
Finnerup NB. Nonnarcotic Methods of Pain Management. N Engl J Med  2019; 380(25): 2440-8.
[http://dx.doi.org/10.1056/NEJMra1807061] [PMID: 31216399] 
[158] 
Jensen TS. Anticonvulsants in neuropathic pain: rationale and clinical evidence. Eur J Pain  2002; 6(Suppl. A): 61-8.
[http://dx.doi.org/10.1053/eujp.2001.0324] [PMID: 11888243] 
[159] 
Rose MA, Kam PC. Gabapentin: pharmacology and its use in pain management. Anaesthesia  2002; 57(5): 451-62.
[http://dx.doi.org/10.1046/j.0003-2409.2001.02399.x] [PMID: 11966555] 
[160] 
Javed S, Alam U, Malik RA. Mirogabalin and emerging therapies for diabetic neuropathy. J Pain Res  2018; 11: 1559-66.
[http://dx.doi.org/10.2147/JPR.S145999] [PMID: 30174455] 
[161] 
Taylor CP. Mechanisms of analgesia by gabapentin and pregabalin--calcium channel alpha2-delta [Cavalpha2-delta] ligands. Pain  2009; 142(1-2): 13-6.
[http://dx.doi.org/10.1016/j.pain.2008.11.019] [PMID: 19128880] 
[162] 
Kukkar A, Bali A, Singh N, Jaggi AS. Implications and mechanism of action of gabapentin in neuropathic pain. Arch Pharm Res  2013; 36(3): 237-51.
[http://dx.doi.org/10.1007/s12272-013-0057-y] [PMID: 23435945] 
[163] 
Bockbrader HN, Wesche D, Miller R, Chapel S, Janiczek N, Burger P. A comparison of the pharmacokinetics and pharmacodynamics of pregabalin and gabapentin. Clin Pharmacokinet  2010; 49(10): 661-9.
[http://dx.doi.org/10.2165/11536200-000000000-00000] [PMID: 20818832] 
[164] 
Bennett MI, Simpson KH. Gabapentin in the treatment of neuropathic pain. Palliat Med  2004; 18(1): 5-11.
[http://dx.doi.org/10.1191/0269216304pm845ra] [PMID: 14982201] 
[165] 
Backonja M, Beydoun A, Edwards KR, et al. Gabapentin for the symptomatic treatment of painful neuropathy in patients with diabetes mellitus: a randomized controlled trial. JAMA  1998; 280(21): 1831-6.
[http://dx.doi.org/10.1001/jama.280.21.1831] [PMID: 9846777] 
[166] 
Gorson KC, Schott C, Herman R, Ropper AH, Rand WM. Gabapentin in the treatment of painful diabetic neuropathy: a placebo controlled, double blind, crossover trial. J Neurol Neurosurg Psychiatry  1999; 66(2): 251-2.
[http://dx.doi.org/10.1136/jnnp.66.2.251] [PMID: 10071116] 
[167] 
Dallocchio C, Buffa C, Mazzarello P, Chiroli S. Gabapentin vs. amitriptyline in painful diabetic neuropathy: an open-label pilot study. J Pain Symptom Manage  2000; 20(4): 280-5.
[http://dx.doi.org/10.1016/S0885-3924(00)00181-0] [PMID: 11027910] 
[168] 
Pérez HE, Sánchez GF. Gabapentin therapy for diabetic neuropathic pain. Am J Med  2000; 108(8): 689.
[http://dx.doi.org/10.1016/S0002-9343(00)00398-3] [PMID: 10896633] 
[169] 
Simpson DA. Gabapentin and venlafaxine for the treatment of painful diabetic neuropathy. J Clin Neuromuscul Dis  2001; 3(2): 53-62.
[http://dx.doi.org/10.1097/00131402-200112000-00002] [PMID: 19078655] 
[170] 
Morello CM, Leckband SG, Stoner CP, Moorhouse DF, Sahagian GA. Randomized double-blind study comparing the efficacy of gabapentin with amitriptyline on diabetic peripheral neuropathy pain. Arch Intern Med  1999; 159(16): 1931-7.
[http://dx.doi.org/10.1001/archinte.159.16.1931] [PMID: 10493324] 
[171] 
Cundy KC, Sastry S, Luo W, Zou J, Moors TL, Canafax DM. Clinical pharmacokinetics of XP13512, a novel transported prodrug of gabapentin. J Clin Pharmacol  2008; 48(12): 1378-88.
[http://dx.doi.org/10.1177/0091270008322909] [PMID: 18827074] 
[172] 
Rauck R, Makumi CW, Schwartz S, et al. A randomized, controlled trial of gabapentin enacarbil in subjects with neuropathic pain associated with diabetic peripheral neuropathy. Pain Pract  2013; 13(6): 485-96.
[http://dx.doi.org/10.1111/papr.12014] [PMID: 23186035] 
[173] 
Sandercock D, Cramer M, Biton V, Cowles VE. A gastroretentive gabapentin formulation for the treatment of painful diabetic peripheral neuropathy: efficacy and tolerability in a double-blind, randomized, controlled clinical trial. Diabetes Res Clin Pract  2012; 97(3): 438-45.
[http://dx.doi.org/10.1016/j.diabres.2012.03.010] [PMID: 22497967] 
[174] 
Rudroju N, Bansal D, Talakokkula ST, et al. Comparative efficacy and safety of six antidepressants and anticonvulsants in painful diabetic neuropathy: a network meta-analysis. Pain Physician  2013; 16(6): E705-14.
[PMID: 24284851] 
[175] 
Dy SM, Bennett WL, Sharma R, et al. Preventing complications and treating symptoms of diabetic peripheral neuropathy. : Agency for Healthcare Research and Quality (US); 2017 Mar. Report No.: 17-EHC005-EF. 2017.
[PMID: 28749633] 
[176] 
Neurontin U.S. Medication Guide 2017.  Available from: http://labeling.pfizer.com/ShowLabeling.aspx?id=630
[177] 
Alam U, Sloan G, Tesfaye S. Treating pain in diabetic neuropathy: Current and developmental drugs. Drugs  2020; 80(4): 363-84.
[http://dx.doi.org/10.1007/s40265-020-01259-2] [PMID: 32040849] 
[178] 
Frampton JE, Scott LJ. Pregabalin: in the treatment of painful diabetic peripheral neuropathy. Drugs  2004; 64(24): 2813-20.
[http://dx.doi.org/10.2165/00003495-200464240-00006] [PMID: 15563250] 
[179] 
Rosenstock J, Tuchman M, LaMoreaux L, Sharma U. Pregabalin for the treatment of painful diabetic peripheral neuropathy: a double-blind, placebo-controlled trial. Pain  2004; 110(3): 628-38.
[http://dx.doi.org/10.1016/j.pain.2004.05.001] [PMID: 15288403] 
[180] 
Lesser H, Sharma U, LaMoreaux L, Poole RM. Pregabalin relieves symptoms of painful diabetic neuropathy: a randomized controlled trial. Neurology  2004; 63(11): 2104-10.
[http://dx.doi.org/10.1212/01.WNL.0000145767.36287.A1] [PMID: 15596757] 
[181] 
Richter RW, Portenoy R, Sharma U, Lamoreaux L, Bockbrader H, Knapp LE. Relief of painful diabetic peripheral neuropathy with pregabalin: a randomized, placebo-controlled trial. J Pain  2005; 6(4): 253-60.
[http://dx.doi.org/10.1016/j.jpain.2004.12.007] [PMID: 15820913] 
[182] 
Freynhagen R, Strojek K, Griesing T, Whalen E, Balkenohl M. Efficacy of pregabalin in neuropathic pain evaluated in a 12-week, randomised, double-blind, multicentre, placebo-controlled trial of flexible- and fixed-dose regimens. Pain  2005; 115(3): 254-63.
[http://dx.doi.org/10.1016/j.pain.2005.02.032] [PMID: 15911152] 
[183] 
Tölle T, Freynhagen R, Versavel M, Trostmann U, Young JP Jr. Pregabalin for relief of neuropathic pain associated with diabetic neuropathy: a randomized, double-blind study. Eur J Pain  2008; 12(2): 203-13.
[http://dx.doi.org/10.1016/j.ejpain.2007.05.003] [PMID: 17631400] 
[184] 
Arezzo JC, Rosenstock J, Lamoreaux L, Pauer L. Efficacy and safety of pregabalin 600 mg/d for treating painful diabetic peripheral neuropathy: a double-blind placebo-controlled trial. BMC Neurol  2008; 8: 33.
[http://dx.doi.org/10.1186/1471-2377-8-33] [PMID: 18796160] 
[185] 
Satoh J, Yagihashi S, Baba M, et al. Efficacy and safety of pregabalin for treating neuropathic pain associated with diabetic peripheral neuropathy: a 14 week, randomized, double-blind, placebo-controlled trial. Diabet Med  2011; 28(1): 109-16.
[http://dx.doi.org/10.1111/j.1464-5491.2010.03152.x] [PMID: 21166852] 
[186] 
Gilron I, Wajsbrot D, Therrien F, Lemay J. Pregabalin for peripheral neuropathic pain: a multicenter, enriched enrollment randomized withdrawal placebo-controlled trial. Clin J Pain  2011; 27(3): 185-93.
[http://dx.doi.org/10.1097/AJP.0b013e3181fe13f6] [PMID: 21178603] 
[187] 
Mu Y, Liu X, Li Q, et al. Efficacy and safety of pregabalin for painful diabetic peripheral neuropathy in a population of Chinese patients: A randomized placebo-controlled trial. J Diabetes  2018; 10(3): 256-65.
[http://dx.doi.org/10.1111/1753-0407.12585] [PMID: 28727270] 
[188] 
Huffman C, Stacey BR, Tuchman M, et al. Efficacy and safety of pregabalin in the treatment of patients with painful diabetic peripheral neuropathy and pain on walking. Clin J Pain  2015; 31(11): 946-58.
[http://dx.doi.org/10.1097/AJP.0000000000000198] [PMID: 25565583] 
[189] 
Raskin P, Huffman C, Toth C, et al. Pregabalin in patients with inadequately treated painful diabetic peripheral neuropathy: a randomized withdrawal trial. Clin J Pain  2014; 30(5): 379-90.
[http://dx.doi.org/10.1097/AJP.0b013e31829ea1a1] [PMID: 23887339] 
[190] 
Raskin P, Huffman C, Yurkewicz L, et al. Pregabalin in patients with painful diabetic peripheral neuropathy using an nsaid for other pain conditions: A double-blind crossover study. Clin J Pain  2016; 32(3): 203-10.
[http://dx.doi.org/10.1097/AJP.0000000000000254] [PMID: 25968451] 
[191] 
Ziegler D, Duan WR, An G, Thomas JW, Nothaft W. A randomized double-blind, placebo-, and active-controlled study of T-type calcium channel blocker ABT-639 in patients with diabetic peripheral neuropathic pain. Pain  2015; 156(10): 2013-20.
[http://dx.doi.org/10.1097/j.pain.0000000000000263] [PMID: 26067585] 
[192] 
Smith T, DiBernardo A, Shi Y, Todd MJ, Brashear HR, Ford LM. Efficacy and safety of carisbamate in patients with diabetic neuropathy or postherpetic neuralgia: results from 3 randomized, double-blind placebo-controlled trials. Pain Pract  2014; 14(4): 332-42.
[http://dx.doi.org/10.1111/papr.12080] [PMID: 23692321] 
[193] 
Vinik A, Rosenstock J, Sharma U, Feins K, Hsu C, Merante D. Efficacy and safety of mirogabalin (DS-5565) for the treatment of diabetic peripheral neuropathic pain: a randomized, double-blind, placebo- and active comparator-controlled, adaptive proof-of-concept phase 2 study. Diabetes Care  2014; 37(12): 3253-61.
[http://dx.doi.org/10.2337/dc14-1044] [PMID: 25231896] 
[194] 
Bansal D, Bhansali A, Hota D, Chakrabarti A, Dutta P. Amitriptyline vs. pregabalin in painful diabetic neuropathy: a randomized double blind clinical trial. Diabet Med  2009; 26(10): 1019-26.
[http://dx.doi.org/10.1111/j.1464-5491.2009.02806.x] [PMID: 19900234] 
[195] 
Boyle J, Eriksson ME, Gribble L, et al. Randomized, placebo-controlled comparison of amitriptyline, duloxetine, and pregabalin in patients with chronic diabetic peripheral neuropathic pain: impact on pain, polysomnographic sleep, daytime functioning, and quality of life. Diabetes Care  2012; 35(12): 2451-8.
[http://dx.doi.org/10.2337/dc12-0656] [PMID: 22991449] 
[196] 
Baron R, Mayoral V, Leijon G, Binder A, Steigerwald I, Serpell M. Efficacy and safety of combination therapy with 5% lidocaine medicated plaster and pregabalin in post-herpetic neuralgia and diabetic polyneuropathy. Curr Med Res Opin  2009; 25(7): 1677-87.
[http://dx.doi.org/10.1185/03007990903048078] [PMID: 19480610] 
[197] 
Freeman R, Durso-Decruz E, Emir B. Efficacy, safety, and tolerability of pregabalin treatment for painful diabetic peripheral neuropathy: findings from seven randomized, controlled trials across a range of doses. Diabetes Care  2008; 31(7): 1448-54.
[http://dx.doi.org/10.2337/dc07-2105] [PMID: 18356405] 
[198] 
Roth T, van Seventer R, Murphy TK. The effect of pregabalin on pain-related sleep interference in diabetic peripheral neuropathy or postherpetic neuralgia: a review of nine clinical trials. Curr Med Res Opin  2010; 26(10): 2411-9.
[http://dx.doi.org/10.1185/03007995.2010.516142] [PMID: 20812792] 
[199] 
Slee A, Nazareth I, Bondaronek P, Liu Y, Cheng Z, Freemantle N. Pharmacological treatments for generalised anxiety disorder: a systematic review and network meta-analysis. Lancet  2019; 393(10173): 768-77.
[http://dx.doi.org/10.1016/S0140-6736(18)31793-8] [PMID: 30712879] 
[200] 
Vinik A, Emir B, Cheung R, Whalen E. Relationship between pain relief and improvements in patient function/quality of life in patients with painful diabetic peripheral neuropathy or postherpetic neuralgia treated with pregabalin. Clin Ther  2013; 35(5): 612-23.
[http://dx.doi.org/10.1016/j.clinthera.2013.03.008] [PMID: 23541708] 
[201] 
 FDA. Product title and initial U.S. approval in the highlights of prescribing information for human prescription drug and biological products - content and format. 2018 Available from: https://www.fda.gov/media/110453/download
[202] 
Parsons B, Emir B. Glycemic and serum lipid control in patients with painful diabetic peripheral neuropathy treated with pregabalin. J Diabetes Complications  2017; 31(2): 489-93.
[http://dx.doi.org/10.1016/j.jdiacomp.2016.03.019] [PMID: 27531675] 
[203] 
Tesfaye S, Wilhelm S, Lledo A, et al. Duloxetine and pregabalin: high-dose monotherapy or their combination? The “COMBO-DN study”--a multinational, randomized, double-blind, parallel-group study in patients with diabetic peripheral neuropathic pain. Pain  2013; 154(12): 2616-25.
[http://dx.doi.org/10.1016/j.pain.2013.05.043] [PMID: 23732189] 
[204] 
Iacobucci G. UK government to reclassify pregabalin and gabapentin after rise in deaths. BMJ  2017; 358: j4441.
[http://dx.doi.org/10.1136/bmj.j4441] [PMID: 28947423] 
[205] 
Evoy KE, Covvey JR, Peckham AM, Ochs L, Hultgren KE. Reports of gabapentin and pregabalin abuse, misuse, dependence, or overdose: An analysis of the Food And Drug Administration Adverse Events Reporting System (FAERS). Res Social Adm Pharm  2019; 15(8): 953-8.
[http://dx.doi.org/10.1016/j.sapharm.2018.06.018] [PMID: 31303196] 
[206] 
Rescheduling of gabapentin and pregabalin as schedule 3 controlled drugs  Available from: https://www.england.nhs.uk/wp-content/uploads/2019/03/pregabalin-and-gabapentin-guidance-v1.pdf2019
[207] 
Bonnet U, Richter EL, Isbruch K, Scherbaum N. On the addictive power of gabapentinoids: a mini-review. Psychiatr Danub  2018; 30(2): 142-9.
[http://dx.doi.org/10.24869/psyd.2018.142] [PMID: 29930223] 
[208] 
Evoy KE, Morrison MD, Saklad SR. Abuse and misuse of pregabalin and gabapentin. Drugs  2017; 77(4): 403-26.
[http://dx.doi.org/10.1007/s40265-017-0700-x] [PMID: 28144823] 
[209] 
Deeks ED. Mirogabalin: First global approval. Drugs  2019; 79(4): 463-8.
[http://dx.doi.org/10.1007/s40265-019-01070-8] [PMID: 30778848] 
[210] 
Baba M, Kuroha M, Ohwada S, Murayama E, Matsui N. Results of mirogabalin treatment for diabetic peripheral neuropathic pain in asian subjects: A phase 2, double-blind, randomized, placebo-controlled, study. Pain Ther  2020; 9(1): 261-78.
[http://dx.doi.org/10.1007/s40122-020-00156-6] [PMID: 32052264] 
[211] 
Baba M, Matsui N, Kuroha M, Wasaki Y, Ohwada S. Mirogabalin for the treatment of diabetic peripheral neuropathic pain: A randomized, double-blind, placebo-controlled phase III study in Asian patients. J Diabetes Investig  2019; 10(5): 1299-306.
[http://dx.doi.org/10.1111/jdi.13013] [PMID: 30672128] 
[212] 
Merante D, Rosenstock J, Sharma U, Feins K, Hsu C, Vinik A. Efficacy of mirogabalin (ds-5565) on patient-reported pain and sleep interference in patients with diabetic neuropathic pain: secondary outcomes of a phase ii proof-of-concept study. Pain Med  2017; 18(11): 2198-207.
[http://dx.doi.org/10.1093/pm/pnw342] [PMID: 28371941] 
[213] 
Eisenberg E, River Y, Shifrin A, Krivoy N. Antiepileptic drugs in the treatment of neuropathic pain. Drugs  2007; 67(9): 1265-89.
[http://dx.doi.org/10.2165/00003495-200767090-00003] [PMID: 17547471] 
[214] 
Rull JA, Quibrera R, González-Millán H, Lozano Castañeda O. Symptomatic treatment of peripheral diabetic neuropathy with carbamazepine (Tegretol): double blind crossover trial. Diabetologia  1969; 5(4): 215-8.
[http://dx.doi.org/10.1007/BF01212087] [PMID: 4902717] 
[215] 
Wilton TD. Tegretol in the treatment of diabetic neuropathy. S Afr Med J  1974; 48(20): 869-72.
[PMID: 4597907] 
[216] 
Gómez-Pérez FJ, Choza R, Ríos JM, et al. Nortriptyline-fluphenazine vs. carbamazepine in the symptomatic treatment of diabetic neuropathy. Arch Med Res  1996; 27(4): 525-9.
[PMID: 8987189] 
[217] 
Hai-Yan J, Qi-Fu L, Song D-P. Effects of venlafaxine and carbamazepine for painful peripheral diabetic neuropathy: A randomized, double-blind and double-dummy, controlled multi-center trial. Chinese journal of evidence-based medicine  2006; 6(5)
[218] 
Razazian N, Baziyar M, Moradian N, Afshari D, Bostani A, Mahmoodi M. Evaluation of the efficacy and safety of pregabalin, venlafaxine, and carbamazepine in patients with painful diabetic peripheral neuropathy. A randomized, double-blind trial. Neurosciences (Riyadh)  2014; 19(3): 192-8.
[PMID: 24983280] 
[219] 
Dogra S, Beydoun S, Mazzola J, Hopwood M, Wan Y. Oxcarbazepine in painful diabetic neuropathy: a randomized, placebo-controlled study. Eur J Pain  2005; 9(5): 543-54.
[http://dx.doi.org/10.1016/j.ejpain.2004.11.006] [PMID: 16139183] 
[220] 
Grosskopf J, Mazzola J, Wan Y, Hopwood M. A randomized, placebo-controlled study of oxcarbazepine in painful diabetic neuropathy. Acta Neurol Scand  2006; 114(3): 177-80.
[http://dx.doi.org/10.1111/j.1600-0404.2005.00559.x] [PMID: 16911345] 
[221] 
Beydoun A, Kobetz SA, Carrazana EJ. Efficacy of oxcarbazepine in the treatment of painful diabetic neuropathy. Clin J Pain  2004; 20(3): 174-8.
[http://dx.doi.org/10.1097/00002508-200405000-00007] [PMID: 15100593] 
[222] 
Thienel U, Neto W, Schwabe SK, Vijapurkar U, Group TDNPS. Topiramate in painful diabetic polyneuropathy: findings from three double-blind placebo-controlled trials. Acta Neurol Scand  2004; 110(4): 221-31.
[http://dx.doi.org/10.1111/j.1600-0404.2004.00338.x] [PMID: 15355485] 
[223] 
Raskin P, Donofrio PD, Rosenthal NR, et al. Topiramate vs placebo in painful diabetic neuropathy: analgesic and metabolic effects. Neurology  2004; 63(5): 865-73.
[http://dx.doi.org/10.1212/01.WNL.0000137341.89781.14] [PMID: 15365138] 
[224] 
Donofrio PD, Raskin P, Rosenthal NR, et al. Safety and effectiveness of topiramate for the management of painful diabetic peripheral neuropathy in an open-label extension study. Clin Ther  2005; 27(9): 1420-31.
[http://dx.doi.org/10.1016/j.clinthera.2005.09.011] [PMID: 16291415] 
[225] 
Boyd AL, Barlow PM, Pittenger GL, Simmons KF, Vinik AI. Topiramate improves neurovascular function, epidermal nerve fiber morphology, and metabolism in patients with type 2 diabetes mellitus. Diabetes Metab Syndr Obes  2010; 3: 431-7.
[http://dx.doi.org/10.2147/DMSO.S13699] [PMID: 21437113] 
[226] 
McCleane GJ. Lamotrigine in the management of neuropathic pain: a review of the literature. Clin J Pain  2000; 16(4): 321-6.
[http://dx.doi.org/10.1097/00002508-200012000-00008] [PMID: 11153788] 
[227] 
Eisenberg E, Lurie Y, Braker C, Daoud D, Ishay A. Lamotrigine reduces painful diabetic neuropathy: a randomized, controlled study. Neurology  2001; 57(3): 505-9.
[http://dx.doi.org/10.1212/WNL.57.3.505] [PMID: 11502921] 
[228] 
Jose VM, Bhansali A, Hota D, Pandhi P. Randomized double-blind study comparing the efficacy and safety of lamotrigine and amitriptyline in painful diabetic neuropathy. Diabet Med  2007; 24(4): 377-83.
[http://dx.doi.org/10.1111/j.1464-5491.2007.02093.x] [PMID: 17335465] 
[229] 
Vinik AI, Tuchman M, Safirstein B, et al. Lamotrigine for treatment of pain associated with diabetic neuropathy: results of two randomized, double-blind, placebo-controlled studies. Pain  2007; 128(1-2): 169-79.
[http://dx.doi.org/10.1016/j.pain.2006.09.040] [PMID: 17161535] 
[230] 
Kochar DK, Jain N, Agarwal RP, Srivastava T, Agarwal P, Gupta S. Sodium valproate in the management of painful neuropathy in type 2 diabetes - a randomized placebo controlled study. Acta Neurol Scand  2002; 106(5): 248-52.
[http://dx.doi.org/10.1034/j.1600-0404.2002.01229.x] [PMID: 12371916] 
[231] 
Kochar DK, Rawat N, Agrawal RP, et al. Sodium valproate for painful diabetic neuropathy: A randomized double-blind placebo-controlled study. QJM  2004; 97(1): 33-8.
[http://dx.doi.org/10.1093/qjmed/hch007] [PMID: 14702509] 
[232] 
Otto M, Bach FW, Jensen TS, Sindrup SH. Valproic acid has no effect on pain in polyneuropathy: a randomized, controlled trial. Neurology  2004; 62(2): 285-8.
[http://dx.doi.org/10.1212/WNL.62.2.285] [PMID: 14745070] 
[233] 
Agrawal RP, Goswami J, Jain S, Kochar DK. Management of diabetic neuropathy by sodium valproate and glyceryl trinitrate spray: a prospective double-blind randomized placebo-controlled study. Diabetes Res Clin Pract  2009; 83(3): 371-8.
[http://dx.doi.org/10.1016/j.diabres.2008.12.018] [PMID: 19208440] 
[234] 
Chadda VS, Mathur MS. Double blind study of the effects of diphenylhydantoin sodium on diabetic neuropathy. J Assoc Physicians India  1978; 26(5): 403-6.
[PMID: 365857] 
[235] 
Saudek CD, Werns S, Reidenberg MM. Phenytoin in the treatment of diabetic symmetrical polyneuropathy. Clin Pharmacol Ther  1977; 22(2): 196-9.
[http://dx.doi.org/10.1002/cpt1977222196] [PMID: 328209] 
[236] 
McCleane GJ. Intravenous infusion of phenytoin relieves neuropathic pain: a randomized, double-blinded, placebo-controlled, crossover study. Anesth Analg  1999; 89(4): 985-8.
[http://dx.doi.org/10.1213/00000539-199910000-00030] [PMID: 10512276] 
[237] 
Kopsky DJ, Keppel Hesselink JM. Topical phenytoin for the treatment of neuropathic pain. J Pain Res  2017; 10: 469-73.
[http://dx.doi.org/10.2147/JPR.S129749] [PMID: 28280381] 
[238] 
Rauck RL, Shaibani A, Biton V, Simpson J, Koch B. Lacosamide in painful diabetic peripheral neuropathy: a phase 2 double-blind placebo-controlled study. Clin J Pain  2007; 23(2): 150-8.
[http://dx.doi.org/10.1097/01.ajp.0000210957.39621.b2] [PMID: 17237664] 
[239] 
Wymer JP, Simpson J, Sen D, Bongardt S, Group LSS. Efficacy and safety of lacosamide in diabetic neuropathic pain: an 18-week double-blind placebo-controlled trial of fixed-dose regimens. Clin J Pain  2009; 25(5): 376-85.
[http://dx.doi.org/10.1097/AJP.0b013e318196d2b6] [PMID: 19454870] 
[240] 
Shaibani A, Fares S, Selam JL, et al. Lacosamide in painful diabetic neuropathy: an 18-week double-blind placebo-controlled trial. J Pain  2009; 10(8): 818-28.
[http://dx.doi.org/10.1016/j.jpain.2009.01.322] [PMID: 19409861] 
[241] 
Ziegler D, Hidvégi T, Gurieva I, et al. Efficacy and safety of lacosamide in painful diabetic neuropathy. Diabetes Care  2010; 33(4): 839-41.
[http://dx.doi.org/10.2337/dc09-1578] [PMID: 20067958] 
[242] 
Atli A, Dogra S. Zonisamide in the treatment of painful diabetic neuropathy: a randomized, double-blind, placebo-controlled pilot study. Pain Med  2005; 6(3): 225-34.
[http://dx.doi.org/10.1111/j.1526-4637.2005.05035.x] [PMID: 15972086] 
[243] 
Sindrup SH, Otto M, Finnerup NB, Jensen TS. Antidepressants in the treatment of neuropathic pain. Basic Clin Pharmacol Toxicol  2005; 96(6): 399-409.
[http://dx.doi.org/10.1111/j.1742-7843.2005.pto_96696601.x] [PMID: 15910402] 
[244] 
Bryson HM, Wilde MI. Amitriptyline. A review of its pharmacological properties and therapeutic use in chronic pain states. Drugs Aging  1996; 8(6): 459-76.
[http://dx.doi.org/10.2165/00002512-199608060-00008] [PMID: 8736630] 
[245] 
Gillman PK. Tricyclic antidepressant pharmacology and therapeutic drug interactions updated. Br J Pharmacol  2007; 151(6): 737-48.
[http://dx.doi.org/10.1038/sj.bjp.0707253] [PMID: 17471183] 
[246] 
Turkington RW. Depression masquerading as diabetic neuropathy. JAMA  1980; 243(11): 1147-50.
[http://dx.doi.org/10.1001/jama.1980.03300370021019] [PMID: 6987418] 
[247] 
Mendel CM, Klein RF, Chappell DA, et al. A trial of amitriptyline and fluphenazine in the treatment of painful diabetic neuropathy. JAMA  1986; 255(5): 637-9.
[http://dx.doi.org/10.1001/jama.1986.03370050079025] [PMID: 3511312] 
[248] 
Max MB, Culnane M, Schafer SC, et al. Amitriptyline relieves diabetic neuropathy pain in patients with normal or depressed mood. Neurology  1987; 37(4): 589-96.
[http://dx.doi.org/10.1212/WNL.37.4.589] [PMID: 2436092] 
[249] 
Max MB, Lynch SA, Muir J, Shoaf SE, Smoller B, Dubner R. Effects of desipramine, amitriptyline, and fluoxetine on pain in diabetic neuropathy. N Engl J Med  1992; 326(19): 1250-6.
[http://dx.doi.org/10.1056/NEJM199205073261904] [PMID: 1560801] 
[250] 
Biesbroeck R, Bril V, Hollander P, et al. A double-blind comparison of topical capsaicin and oral amitriptyline in painful diabetic neuropathy. Adv Ther  1995; 12(2): 111-20.
[PMID: 10150323] 
[251] 
Vrethem M, Boivie J, Arnqvist H, Holmgren H, Lindström T, Thorell LH. A comparison a amitriptyline and maprotiline in the treatment of painful polyneuropathy in diabetics and nondiabetics. Clin J Pain  1997; 13(4): 313-23.
[http://dx.doi.org/10.1097/00002508-199712000-00009] [PMID: 9430812] 
[252] 
Kaur H, Hota D, Bhansali A, Dutta P, Bansal D, Chakrabarti A. A comparative evaluation of amitriptyline and duloxetine in painful diabetic neuropathy: a randomized, double-blind, cross-over clinical trial. Diabetes Care  2011; 34(4): 818-22.
[http://dx.doi.org/10.2337/dc10-1793] [PMID: 21355098] 
[253] 
Kiani J, Ahmad Nasrollahi S, Esna-Ashari F, Fallah P, Sajedi F. Amitriptyline 2% cream vs. capsaicin 0.75% cream in the treatment of painful diabetic neuropathy (Double blind, randomized clinical trial of efficacy and safety). Iran J Pharm Res  2015; 14(4): 1263-8.
[PMID: 26664395] 
[254] 
Lynch ME, Clark AJ, Sawynok J, Sullivan MJ. Topical 2% amitriptyline and 1% ketamine in neuropathic pain syndromes: a randomized, double-blind, placebo-controlled trial. Anesthesiology  2005; 103(1): 140-6.
[http://dx.doi.org/10.1097/00000542-200507000-00021] [PMID: 15983466] 
[255] 
Ho KY, Huh BK, White WD, Yeh CC, Miller EJ. Topical amitriptyline versus lidocaine in the treatment of neuropathic pain. Clin J Pain  2008; 24(1): 51-5.
[http://dx.doi.org/10.1097/AJP.0b013e318156db26] [PMID: 18180637] 
[256] 
Kvinesdal B, Molin J, Frøland A, Gram LF. Imipramine treatment of painful diabetic neuropathy. JAMA  1984; 251(13): 1727-30.
[http://dx.doi.org/10.1001/jama.1984.03340370059031] [PMID: 6366276] 
[257] 
Sindrup SH, Ejlertsen B, Frøland A, Sindrup EH, Brøsen K, Gram LF. Imipramine treatment in diabetic neuropathy: relief of subjective symptoms without changes in peripheral and autonomic nerve function. Eur J Clin Pharmacol  1989; 37(2): 151-3.
[http://dx.doi.org/10.1007/BF00558223] [PMID: 2792168] 
[258] 
Sindrup SH, Gram LF, Brøsen K, Eshøj O, Mogensen EF. The selective serotonin reuptake inhibitor paroxetine is effective in the treatment of diabetic neuropathy symptoms. Pain  1990; 42(2): 135-44.
[http://dx.doi.org/10.1016/0304-3959(90)91157-E] [PMID: 2147235] 
[259] 
Sindrup SH, Bach FW, Madsen C, Gram LF, Jensen TS. Venlafaxine versus imipramine in painful polyneuropathy: a randomized, controlled trial. Neurology  2003; 60(8): 1284-9.
[http://dx.doi.org/10.1212/01.WNL.0000058749.49264.BD] [PMID: 12707430] 
[260] 
Sindrup SH, Tuxen C, Gram LF, et al. Lack of effect of mianserin on the symptoms of diabetic neuropathy. Eur J Clin Pharmacol  1992; 43(3): 251-5.
[http://dx.doi.org/10.1007/BF02333018] [PMID: 1425887] 
[261] 
Max MB, Kishore-Kumar R, Schafer SC, et al. Efficacy of desipramine in painful diabetic neuropathy: a placebo-controlled trial. Pain  1991; 45(1): 3-9.
[http://dx.doi.org/10.1016/0304-3959(91)90157-S] [PMID: 1861872] 
[262] 
Sindrup SH, Gram LF, Skjold T, Grodum E, Brøsen K, Beck-Nielsen H. Clomipramine vs desipramine vs placebo in the treatment of diabetic neuropathy symptoms. A double-blind cross-over study. Br J Clin Pharmacol  1990; 30(5): 683-91.
[http://dx.doi.org/10.1111/j.1365-2125.1990.tb03836.x] [PMID: 2271367] 
[263] 
Gomez-Perez FJ, Rull JA, Dies H, Rodriguez-Rivera GJ, Gonzalez-Barranco J, Lozano-Castañeda O. Nortriptyline and fluphenazine in the symptomatic treatment of diabetic neuropathy. A double-blind cross-over study. Pain  1985; 23(4): 395-400.
[http://dx.doi.org/10.1016/0304-3959(85)90010-7] [PMID: 3911140] 
[264] 
Gilron I, Bailey JM, Tu D, Holden RR, Jackson AC, Houlden RL. Nortriptyline and gabapentin, alone and in combination for neuropathic pain: a double-blind, randomised controlled crossover trial. Lancet  2009; 374(9697): 1252-61.
[http://dx.doi.org/10.1016/S0140-6736(09)61081-3] [PMID: 19796802] 
[265] 
Joss JD. Tricyclic antidepressant use in diabetic neuropathy. Ann Pharmacother  1999; 33(9): 996-1000.
[http://dx.doi.org/10.1345/aph.18431] [PMID: 10492505] 
[266] 
Marks DM, Shah MJ, Patkar AA, Masand PS, Park GY, Pae CU. Serotonin-norepinephrine reuptake inhibitors for pain control: premise and promise. Curr Neuropharmacol  2009; 7(4): 331-6.
[http://dx.doi.org/10.2174/157015909790031201] [PMID: 20514212] 
[267] 
Knadler MP, Lobo E, Chappell J, Bergstrom R. Duloxetine: clinical pharmacokinetics and drug interactions. Clin Pharmacokinet  2011; 50(5): 281-94.
[http://dx.doi.org/10.2165/11539240-000000000-00000] [PMID: 21366359] 
[268] 
Goldstein DJ, Lu Y, Detke MJ, Lee TC, Iyengar S. Duloxetine vs. placebo in patients with painful diabetic neuropathy. Pain  2005; 116(1-2): 109-18.
[http://dx.doi.org/10.1016/j.pain.2005.03.029] [PMID: 15927394] 
[269] 
Raskin J, Pritchett YL, Wang F, et al. A double-blind, randomized multicenter trial comparing duloxetine with placebo in the management of diabetic peripheral neuropathic pain. Pain Med  2005; 6(5): 346-56.
[http://dx.doi.org/10.1111/j.1526-4637.2005.00061.x] [PMID: 16266355] 
[270] 
Wernicke JF, Pritchett YL, D’Souza DN, et al. A randomized controlled trial of duloxetine in diabetic peripheral neuropathic pain. Neurology  2006; 67(8): 1411-20.
[http://dx.doi.org/10.1212/01.wnl.0000240225.04000.1a] [PMID: 17060567] 
[271] 
Gao Y, Ning G, Jia WP, et al. Duloxetine versus placebo in the treatment of patients with diabetic neuropathic pain in China. Chin Med J (Engl)  2010; 123(22): 3184-92.
[PMID: 21163113] 
[272] 
Yasuda H, Hotta N, Nakao K, Kasuga M, Kashiwagi A, Kawamori R. Superiority of duloxetine to placebo in improving diabetic neuropathic pain: Results of a randomized controlled trial in Japan. J Diabetes Investig  2011; 2(2): 132-9.
[http://dx.doi.org/10.1111/j.2040-1124.2010.00073.x] [PMID: 24843472] 
[273] 
Gao Y, Guo X, Han P, et al. Treatment of patients with diabetic peripheral neuropathic pain in China: a double-blind randomised trial of duloxetine vs. placebo. Int J Clin Pract  2015; 69(9): 957-66.
[http://dx.doi.org/10.1111/ijcp.12641] [PMID: 25939897] 
[274] 
Rowbotham MC, Arslanian A, Nothaft W, et al. Efficacy and safety of the α4β2 neuronal nicotinic receptor agonist ABT-894 in patients with diabetic peripheral neuropathic pain. Pain  2012; 153(4): 862-8.
[http://dx.doi.org/10.1016/j.pain.2012.01.009] [PMID: 22386472] 
[275] 
Enomoto H, Yasuda H, Nishiyori A, et al. Duloxetine in patients with diabetic peripheral neuropathic pain in Japan: a randomized, doubleblind, noninferiority comparative study with pregabalin. J Pain Res  2018; 11: 1857-68.
[http://dx.doi.org/10.2147/JPR.S170646] [PMID: 30271191] 
[276] 
Majdinasab N, Kaveyani H, Azizi M. A comparative double-blind randomized study on the effectiveness of Duloxetine and Gabapentin on painful diabetic peripheral polyneuropathy. Drug Des Devel Ther  2019; 13: 1985-92.
[http://dx.doi.org/10.2147/DDDT.S185995] [PMID: 31354243] 
[277] 
Brunton S, Wang F, Edwards SB, et al. Profile of adverse events with duloxetine treatment: a pooled analysis of placebo-controlled studies. Drug Saf  2010; 33(5): 393-407.
[http://dx.doi.org/10.2165/11319200-000000000-00000] [PMID: 20397739] 
[278] 
Rowbotham MC, Goli V, Kunz NR, Lei D. Venlafaxine extended release in the treatment of painful diabetic neuropathy: a double-blind, placebo-controlled study. Pain  2004; 110(3): 697-706.
[http://dx.doi.org/10.1016/j.pain.2004.05.010] [PMID: 15288411] 
[279] 
Allen R, Sharma U, Barlas S. Clinical experience with desvenlafaxine in treatment of pain associated with diabetic peripheral neuropathy. J Pain Res  2014; 7: 339-51.
[http://dx.doi.org/10.2147/JPR.S55682] [PMID: 25018648] 
[280] 
Davis JL. Use of sibutramine hydrochloride monohydrate in the treatment of the painful peripheral neuropathy of diabetes. Diabetes Care  2000; 23(10): 1594-5.
[http://dx.doi.org/10.2337/diacare.23.10.1594] [PMID: 11023158] 
[281] 
Sindrup SH, Bjerre U, Dejgaard A, Brøsen K, Aaes-Jørgensen T, Gram LF. The selective serotonin reuptake inhibitor citalopram relieves the symptoms of diabetic neuropathy. Clin Pharmacol Ther  1992; 52(5): 547-52.
[http://dx.doi.org/10.1038/clpt.1992.183] [PMID: 1424428] 
[282] 
Rosenblum A, Marsch LA, Joseph H, Portenoy RK. Opioids and the treatment of chronic pain: controversies, current status, and future directions. Exp Clin Psychopharmacol  2008; 16(5): 405-16.
[http://dx.doi.org/10.1037/a0013628] [PMID: 18837637] 
[283] 
Grond S, Sablotzki A. Clinical pharmacology of tramadol. Clin Pharmacokinet  2004; 43(13): 879-923.
[http://dx.doi.org/10.2165/00003088-200443130-00004] [PMID: 15509185] 
[284] 
Harati Y, Gooch C, Swenson M, et al. Double-blind randomized trial of tramadol for the treatment of the pain of diabetic neuropathy. Neurology  1998; 50(6): 1842-6.
[http://dx.doi.org/10.1212/WNL.50.6.1842] [PMID: 9633738] 
[285] 
Freeman R, Raskin P, Hewitt DJ, et al. Randomized study of tramadol/acetaminophen versus placebo in painful diabetic peripheral neuropathy. Curr Med Res Opin  2007; 23(1): 147-61.
[http://dx.doi.org/10.1185/030079906X162674] [PMID: 17257476] 
[286] 
Sindrup SH, Konder R, Lehmann R, et al. Randomized controlled trial of the combined monoaminergic and opioid investigational compound GRT9906 in painful polyneuropathy. Eur J Pain  2012; 16(6): 849-59.
[http://dx.doi.org/10.1002/j.1532-2149.2011.00069.x] [PMID: 22337471] 
[287] 
Sindrup SH, Andersen G, Madsen C, Smith T, Brøsen K, Jensen TS. Tramadol relieves pain and allodynia in polyneuropathy: a randomised, double-blind, controlled trial. Pain  1999; 83(1): 85-90.
[http://dx.doi.org/10.1016/S0304-3959(99)00079-2] [PMID: 10506675] 
[288] 
Hoy SM. Tapentadol extended release: in adults with chronic pain. Drugs  2012; 72(3): 375-93.
[http://dx.doi.org/10.2165/11208600-000000000-00000] [PMID: 22316353] 
[289] 
Schwartz S, Etropolski M, Shapiro DY, et al. Safety and efficacy of tapentadol ER in patients with painful diabetic peripheral neuropathy: results of a randomized-withdrawal, placebo-controlled trial. Curr Med Res Opin  2011; 27(1): 151-62.
[http://dx.doi.org/10.1185/03007995.2010.537589] [PMID: 21162697] 
[290] 
Vinik AI, Shapiro DY, Rauschkolb C, et al. A randomized withdrawal, placebo-controlled study evaluating the efficacy and tolerability of tapentadol extended release in patients with chronic painful diabetic peripheral neuropathy. Diabetes Care  2014; 37(8): 2302-9.
[http://dx.doi.org/10.2337/dc13-2291] [PMID: 24848284] 
[291] 
Niesters M, Proto PL, Aarts L, Sarton EY, Drewes AM, Dahan A. Tapentadol potentiates descending pain inhibition in chronic pain patients with diabetic polyneuropathy. Br J Anaesth  2014; 113(1): 148-56.
[http://dx.doi.org/10.1093/bja/aeu056] [PMID: 24713310] 
[292] 
Gilron I, Bailey JM, Tu D, Holden RR, Weaver DF, Houlden RL. Morphine, gabapentin, or their combination for neuropathic pain. N Engl J Med  2005; 352(13): 1324-34.
[http://dx.doi.org/10.1056/NEJMoa042580] [PMID: 15800228] 
[293] 
Watson CP, Moulin D, Watt-Watson J, Gordon A, Eisenhoffer J. Controlled-release oxycodone relieves neuropathic pain: a randomized controlled trial in painful diabetic neuropathy. Pain  2003; 105(1-2): 71-8.
[http://dx.doi.org/10.1016/S0304-3959(03)00160-X] [PMID: 14499422] 
[294] 
Gimbel JS, Richards P, Portenoy RK. Controlled-release oxycodone for pain in diabetic neuropathy: a randomized controlled trial. Neurology  2003; 60(6): 927-34.
[http://dx.doi.org/10.1212/01.WNL.0000057720.36503.2C] [PMID: 12654955] 
[295] 
Hanna M, O’Brien C, Wilson MC. Prolonged-release oxycodone enhances the effects of existing gabapentin therapy in painful diabetic neuropathy patients. Eur J Pain  2008; 12(6): 804-13.
[http://dx.doi.org/10.1016/j.ejpain.2007.12.010] [PMID: 18262450] 
[296] 
Simpson RW, Wlodarczyk JH. Transdermal buprenorphine relieves neuropathic pain: A randomized, double-blind, parallel-group, placebo-controlled trial in diabetic peripheral neuropathic pain. Diabetes Care  2016; 39(9): 1493-500.
[http://dx.doi.org/10.2337/dc16-0123] [PMID: 27311495] 
[297] 
Busse JW, Wang L, Kamaleldin M, et al. Opioids for chronic noncancer pain: A systematic review and meta-analysis. JAMA  2018; 320(23): 2448-60.
[http://dx.doi.org/10.1001/jama.2018.18472] [PMID: 30561481] 
[298] 
Fountas A, Van Uum S, Karavitaki N. Opioid-induced endocrinopathies. Lancet Diabetes Endocrinol  2020; 8(1): 68-80.
[http://dx.doi.org/10.1016/S2213-8587(19)30254-2] [PMID: 31624023] 
[299] 
Vowles KE, McEntee ML, Julnes PS, Frohe T, Ney JP, van der Goes DN. Rates of opioid misuse, abuse, and addiction in chronic pain: a systematic review and data synthesis. Pain  2015; 156(4): 569-76.
[http://dx.doi.org/10.1097/01.j.pain.0000460357.01998.f1] [PMID: 25785523] 
[300] 
Bohnert ASB, Valenstein M, Bair MJ, et al. Association between opioid prescribing patterns and opioid overdose-related deaths. JAMA  2011; 305(13): 1315-21.
[http://dx.doi.org/10.1001/jama.2011.370] [PMID: 21467284] 
[301] 
Kozma CM, Benson C, Slaton TL, Kim MS, Vorsanger GJ. Opioids before and after initiation of pregabalin in patients with diabetic peripheral neuropathy. Curr Med Res Opin  2012; 28(9): 1485-96.
[http://dx.doi.org/10.1185/03007995.2012.713338] [PMID: 22856535] 
[302] 
Balhara YPS, Singh S, Kalra S. Pragmatic opioid use in painful diabetic neuropathy. Eur Endocrinol  2020; 16(1): 21-4.
[http://dx.doi.org/10.17925/EE.2020.16.1.21] [PMID: 32595765] 
[303] 
Nelson KA, Park KM, Robinovitz E, Tsigos C, Max MB. High-dose oral dextromethorphan versus placebo in painful diabetic neuropathy and postherpetic neuralgia. Neurology  1997; 48(5): 1212-8.
[http://dx.doi.org/10.1212/WNL.48.5.1212] [PMID: 9153445] 
[304] 
Amin P, Sturrock ND. A pilot study of the beneficial effects of amantadine in the treatment of painful diabetic peripheral neuropathy. Diabet Med  2003; 20(2): 114-8.
[http://dx.doi.org/10.1046/j.1464-5491.2003.00882.x] [PMID: 12581262] 
[305] 
Shaibani AI, Pope LE, Thisted R, Hepner A. Efficacy and safety of dextromethorphan/quinidine at two dosage levels for diabetic neuropathic pain: a double-blind, placebo-controlled, multicenter study. Pain Med  2012; 13(2): 243-54.
[http://dx.doi.org/10.1111/j.1526-4637.2011.01316.x] [PMID: 22314263] 
[306] 
Lakhan SE, Velasco DN, Tepper D. Botulinum toxin-a for painful diabetic neuropathy: A meta-analysis. Pain Med  2015; 16(9): 1773-80.
[http://dx.doi.org/10.1111/pme.12728] [PMID: 25800040] 
[307] 
Yuan RY, Sheu JJ, Yu JM, et al. Botulinum toxin for diabetic neuropathic pain: a randomized double-blind crossover trial. Neurology  2009; 72(17): 1473-8.
[http://dx.doi.org/10.1212/01.wnl.0000345968.05959.cf] [PMID: 19246421] 
[308] 
Ghasemi M, Ansari M, Basiri K, Shaigannejad V. The effects of intradermal botulinum toxin type a injections on pain symptoms of patients with diabetic neuropathy. J Res Med Sci  2014; 19(2): 106-11.
[PMID: 24778662] 
[309] 
Chen WT, Yuan RY, Chiang SC, et al. OnabotulinumtoxinA improves tactile and mechanical pain perception in painful diabetic polyneuropathy. Clin J Pain  2013; 29(4): 305-10.
[http://dx.doi.org/10.1097/AJP.0b013e318255c132] [PMID: 23462284] 
[310] 
Salehi H, Moussaei M, Kamiab Z, Vakilian A. The effects of botulinum toxin type A injection on pain symptoms, quality of life, and sleep quality of patients with diabetic neuropathy: A randomized double-blind clinical trial. Iran J Neurol  2019; 18(3): 99-107.
[http://dx.doi.org/10.18502/ijnl.v18i3.1632] [PMID: 31749930] 
[311] 
Attal N, de Andrade DC, Adam F, et al. Safety and efficacy of repeated injections of botulinum toxin A in peripheral neuropathic pain (BOTNEP): a randomised, double-blind, placebo-controlled trial. Lancet Neurol  2016; 15(6): 555-65.
[http://dx.doi.org/10.1016/S1474-4422(16)00017-X] [PMID: 26947719] 
[312] 
Hill KP, Palastro MD, Johnson B, Ditre JW. Cannabis and pain: A clinical review. Cannabis Cannabinoid Res  2017; 2(1): 96-104.
[http://dx.doi.org/10.1089/can.2017.0017] [PMID: 28861509] 
[313] 
Vučković S, Srebro D, Vujović KS, Vučetić Č, Prostran M. Cannabinoids and pain: New insights from old molecules. Front Pharmacol  2018; 9: 1259.
[http://dx.doi.org/10.3389/fphar.2018.01259] [PMID: 30542280] 
[314] 
Selvarajah D, Gandhi R, Emery CJ, Tesfaye S. Randomized placebo-controlled double-blind clinical trial of cannabis-based medicinal product (Sativex) in painful diabetic neuropathy: depression is a major confounding factor. Diabetes Care  2010; 33(1): 128-30.
[http://dx.doi.org/10.2337/dc09-1029] [PMID: 19808912] 
[315] 
Toth C, Mawani S, Brady S, et al. An enriched-enrolment, randomized withdrawal, flexible-dose, double-blind, placebo-controlled, parallel assignment efficacy study of nabilone as adjuvant in the treatment of diabetic peripheral neuropathic pain. Pain  2012; 153(10): 2073-82.
[http://dx.doi.org/10.1016/j.pain.2012.06.024] [PMID: 22921260] 
[316] 
Reyes-Escogido MdeL, Gonzalez-Mondragon EG, Vazquez-Tzompantzi E. Chemical and pharmacological aspects of capsaicin. Molecules  2011; 16(2): 1253-70.
[http://dx.doi.org/10.3390/molecules16021253] [PMID: 21278678] 
[317] 
Effect of treatment with capsaicin on daily activities of patients with painful diabetic neuropathy. Diabetes Care  1992; 15(2): 159-65.
[http://dx.doi.org/10.2337/diacare.15.2.159] [PMID: 1547671] 
[318] 
Treatment of painful diabetic neuropathy with topical capsaicin. A multicenter, double-blind, vehicle-controlled study. Arch Intern Med  1991; 151(11): 2225-9.
[http://dx.doi.org/10.1001/archinte.1991.00400110079017] [PMID: 1953227] 
[319] 
Kulkantrakorn K, Lorsuwansiri C, Meesawatsom P. 0.025% capsaicin gel for the treatment of painful diabetic neuropathy: a randomized, double-blind, crossover, placebo-controlled trial. Pain Pract  2013; 13(6): 497-503.
[http://dx.doi.org/10.1111/papr.12013] [PMID: 23228119] 
[320] 
Kulkantrakorn K, Chomjit A, Sithinamsuwan P, Tharavanij T, Suwankanoknark J, Napunnaphat P. 0.075% capsaicin lotion for the treatment of painful diabetic neuropathy: A randomized, double-blind, crossover, placebo-controlled trial. J Clin Neurosci  2019; 62: 174-9.
[http://dx.doi.org/10.1016/j.jocn.2018.11.036] [PMID: 30472337] 
[321] 
Low PA, Opfer-Gehrking TL, Dyck PJ, Litchy WJ, O’Brien PC. Double-blind, placebo-controlled study of the application of capsaicin cream in chronic distal painful polyneuropathy. Pain  1995; 62(2): 163-8.
[http://dx.doi.org/10.1016/0304-3959(94)00261-C] [PMID: 8545141] 
[322] 
Kiani J, Sajedi F, Nasrollahi SA, Esna-Ashari F. A randomized clinical trial of efficacy and safety of the topical clonidine and capsaicin in the treatment of painful diabetic neuropathy. J Res Med Sci  2015; 20(4): 359-63.
[PMID: 26109991] 
[323] 
Simpson DM, Robinson-Papp J, Van J, et al. Capsaicin 8% patch in painful diabetic peripheral neuropathy: A randomized, double-blind, placebo-controlled study. J Pain  2017; 18(1): 42-53.
[http://dx.doi.org/10.1016/j.jpain.2016.09.008] [PMID: 27746370] 
[324] 
Vinik AI, Perrot S, Vinik EJ, et al. Capsaicin 8% patch repeat treatment plus standard of care (SOC) versus SOC alone in painful diabetic peripheral neuropathy: a randomised, 52-week, open-label, safety study. BMC Neurol  2016; 16(1): 251.
[http://dx.doi.org/10.1186/s12883-016-0752-7] [PMID: 27919222] 
[325] 
Polydefkis M, Hauer P, Sheth S, Sirdofsky M, Griffin JW, McArthur JC. The time course of epidermal nerve fibre regeneration: studies in normal controls and in people with diabetes, with and without neuropathy. Brain  2004; 127(Pt 7): 1606-15.
[http://dx.doi.org/10.1093/brain/awh175] [PMID: 15128618] 
[326] 
Gibbons CH, Wang N, Freeman R. Capsaicin induces degeneration of cutaneous autonomic nerve fibers. Ann Neurol  2010; 68(6): 888-98.
[http://dx.doi.org/10.1002/ana.22126] [PMID: 21061393] 
[327] 
Barbano RL, Herrmann DN, Hart-Gouleau S, Pennella-Vaughan J, Lodewick PA, Dworkin RH. Effectiveness, tolerability, and impact on quality of life of the 5% lidocaine patch in diabetic polyneuropathy. Arch Neurol  2004; 61(6): 914-8.
[http://dx.doi.org/10.1001/archneur.61.6.914] [PMID: 15210530] 
[328] 
Argoff CE, Galer BS, Jensen MP, Oleka N, Gammaitoni AR. Effectiveness of the lidocaine patch 5% on pain qualities in three chronic pain states: assessment with the Neuropathic Pain Scale. Curr Med Res Opin  2004; 20(Suppl. 2): S21-8.
[http://dx.doi.org/10.1185/030079904X12960] [PMID: 15563743] 
[329] 
Baron R, Mayoral V, Leijon G, Binder A, Steigerwald I, Serpell M. 5% lidocaine medicated plaster versus pregabalin in post-herpetic neuralgia and diabetic polyneuropathy: an open-label, non-inferiority two-stage RCT study. Curr Med Res Opin  2009; 25(7): 1663-76.
[http://dx.doi.org/10.1185/03007990903047880] [PMID: 19485723] 
[330] 
Casale R, Symeonidou Z, Bartolo M. Topical treatments for localized neuropathic pain. Curr Pain Headache Rep  2017; 21(3): 15.
[http://dx.doi.org/10.1007/s11916-017-0615-y] [PMID: 28271334] 
[331] 
Campbell CM, Kipnes MS, Stouch BC, et al. Randomized control trial of topical clonidine for treatment of painful diabetic neuropathy. Pain  2012; 153(9): 1815-23.
[http://dx.doi.org/10.1016/j.pain.2012.04.014] [PMID: 22683276] 
[332] 
Zeigler D, Lynch SA, Muir J, Benjamin J, Max MB. Transdermal clonidine versus placebo in painful diabetic neuropathy. Pain  1992; 48(3): 403-8.
[http://dx.doi.org/10.1016/0304-3959(92)90092-P] [PMID: 1594263] 
[333] 
Byas-Smith MG, Max MB, Muir J, Kingman A. Transdermal clonidine compared to placebo in painful diabetic neuropathy using a two-stage ‘enriched enrollment’ design. Pain  1995; 60(3): 267-74.
[http://dx.doi.org/10.1016/0304-3959(94)00121-T] [PMID: 7596622] 
[334] 
Cohen KL, Lucibello FE, Chomiak M. Lack of effect of clonidine and pentoxifylline in short-term therapy of diabetic peripheral neuropathy. Diabetes Care  1990; 13(10): 1074-7.
[http://dx.doi.org/10.2337/diacare.13.10.1074] [PMID: 2209305] 
[335] 
Yuen KC, Baker NR, Rayman G. Treatment of chronic painful diabetic neuropathy with isosorbide dinitrate spray: a double-blind placebo-controlled cross-over study. Diabetes Care  2002; 25(10): 1699-703.
[http://dx.doi.org/10.2337/diacare.25.10.1699] [PMID: 12351464] 
[336] 
Rayman G, Baker NR, Krishnan ST. Glyceryl trinitrate patches as an alternative to isosorbide dinitrate spray in the treatment of chronic painful diabetic neuropathy. Diabetes Care  2003; 26(9): 2697-8.
[http://dx.doi.org/10.2337/diacare.26.9.2697-a] [PMID: 12941745] 
[337] 
Agrawal RP, Choudhary R, Sharma P, et al. Glyceryl trinitrate spray in the management of painful diabetic neuropathy: a randomized double blind placebo controlled cross-over study. Diabetes Res Clin Pract  2007; 77(2): 161-7.
[http://dx.doi.org/10.1016/j.diabres.2006.12.003] [PMID: 17316865] 
[338] 
Agrawal RP, Jain S, Goyal S, Singhal S, Lindgren L, Sthengel E. A Clinical Trial of Nitrosense patch for the treatment of patients with painful diabetic neuropathy. J Assoc Physicians India  2014; 62(5): 385-90.
[PMID: 25438482] 
[339] 
Mahoney JM, Vardaxis V, Moore JL, Hall AM, Haffner KE, Peterson MC. Topical ketamine cream in the treatment of painful diabetic neuropathy: a randomized, placebo-controlled, double-blind initial study. J Am Podiatr Med Assoc  2012; 102(3): 178-83.
[http://dx.doi.org/10.7547/1020178] [PMID: 22659759] 
[340] 
Kastrup J, Angelo H, Petersen P, Dejgård A, Hilsted J. Treatment of chronic painful diabetic neuropathy with intravenous lidocaine infusion. Br Med J (Clin Res Ed)  1986; 292(6514): 173.
[http://dx.doi.org/10.1136/bmj.292.6514.173] [PMID: 3080123] 
[341] 
Viola V, Newnham HH, Simpson RW. Treatment of intractable painful diabetic neuropathy with intravenous lignocaine. J Diabetes Complications  2006; 20(1): 34-9.
[http://dx.doi.org/10.1016/j.jdiacomp.2005.05.007] [PMID: 16389165] 
[342] 
Moulin DE, Morley-Forster PK, Pirani Z, Rohfritsch C, Stitt L. Intravenous lidocaine in the management of chronic peripheral neuropathic pain: a randomized-controlled trial. Can J Anaesth  2019; 66(7): 820-7.
[http://dx.doi.org/10.1007/s12630-019-01395-8] [PMID: 31098961] 
[343] 
Jarvis B, Coukell AJ. Mexiletine. A review of its therapeutic use in painful diabetic neuropathy. Drugs  1998; 56(4): 691-707.
[http://dx.doi.org/10.2165/00003495-199856040-00016] [PMID: 9806111] 
[344] 
Dejgard A, Petersen P, Kastrup J. Mexiletine for treatment of chronic painful diabetic neuropathy. Lancet  1988; 1(8575-6): 9-11.
[http://dx.doi.org/10.1016/S0140-6736(88)90999-3] [PMID: 2891940] 
[345] 
Wright JM, Oki JC, Graves L III. Mexiletine in the symptomatic treatment of diabetic peripheral neuropathy. Ann Pharmacother  1997; 31(1): 29-34.
[http://dx.doi.org/10.1177/106002809703100103] [PMID: 8997461] 
[346] 
Stracke H, Meyer UE, Schumacher HE, Federlin K. Mexiletine in the treatment of diabetic neuropathy. Diabetes Care  1992; 15(11): 1550-5.
[http://dx.doi.org/10.2337/diacare.15.11.1550] [PMID: 1468285] 
[347] 
Oskarsson P, Ljunggren JG, Lins PE. Efficacy and safety of mexiletine in the treatment of painful diabetic neuropathy. Diabetes Care  1997; 20(10): 1594-7.
[http://dx.doi.org/10.2337/diacare.20.10.1594] [PMID: 9314641] 
[348] 
Dworkin RH, O’Connor AB, Kent J, et al. Interventional management of neuropathic pain: NeuPSIG recommendations. Pain  2013; 154(11): 2249-61.
[http://dx.doi.org/10.1016/j.pain.2013.06.004] [PMID: 23748119] 
[349] 
Raghu ALB, Parker T, Aziz TZ, et al. Invasive electrical neuromodulation for the treatment of painful diabetic neuropathy: Systematic review and meta-analysis. Neuromodulation  2021; 24(1): 13-21.
[http://dx.doi.org/10.1111/ner.13216] [PMID: 32588933] 
[350] 
Zhang TC, Janik JJ, Grill WM. Mechanisms and models of spinal cord stimulation for the treatment of neuropathic pain. Brain Res  2014; 1569: 19-31.
[http://dx.doi.org/10.1016/j.brainres.2014.04.039] [PMID: 24802658] 
[351] 
Tesfaye S, Watt J, Benbow SJ, Pang KA, Miles J, MacFarlane IA. Electrical spinal-cord stimulation for painful diabetic peripheral neuropathy. Lancet  1996; 348(9043): 1698-701.
[http://dx.doi.org/10.1016/S0140-6736(96)02467-1] [PMID: 8973433] 
[352] 
de Vos CC, Meier K, Zaalberg PB, et al. Spinal cord stimulation in patients with painful diabetic neuropathy: a multicentre randomized clinical trial. Pain  2014; 155(11): 2426-31.
[http://dx.doi.org/10.1016/j.pain.2014.08.031] [PMID: 25180016] 
[353] 
Slangen R, Schaper NC, Faber CG, et al. Spinal cord stimulation and pain relief in painful diabetic peripheral neuropathy: a prospective two-center randomized controlled trial. Diabetes Care  2014; 37(11): 3016-24.
[http://dx.doi.org/10.2337/dc14-0684] [PMID: 25216508] 
[354] 
van Beek M, Geurts JW, Slangen R, et al. Severity of neuropathy is associated with long-term spinal cord stimulation outcome in painful diabetic peripheral neuropathy: Five-year follow-up of a prospective two-center clinical trial. Diabetes Care  2018; 41(1): 32-8.
[http://dx.doi.org/10.2337/dc17-0983] [PMID: 29109298] 
[355] 
de Vos CC, Bom MJ, Vanneste S, Lenders MW, de Ridder D. Burst spinal cord stimulation evaluated in patients with failed back surgery syndrome and painful diabetic neuropathy. Neuromodulation  2014; 17(2): 152-9.
[http://dx.doi.org/10.1111/ner.12116] [PMID: 24655043] 
[356] 
Eldabe S, Espinet A, Wahlstedt A, et al. Retrospective case series on the treatment of painful diabetic peripheral neuropathy with dorsal root ganglion stimulation. Neuromodulation  2018; 21(8): 787-92.
[http://dx.doi.org/10.1111/ner.12767] [PMID: 29575331] 
[357] 
Albers JW, Jacobson R. Decompression nerve surgery for diabetic neuropathy: a structured review of published clinical trials. Diabetes Metab Syndr Obes  2018; 11: 493-514.
[http://dx.doi.org/10.2147/DMSO.S146121] [PMID: 30310297] 
[358] 
Low PA, Nickander KK, Tritschler HJ. The roles of oxidative stress and antioxidant treatment in experimental diabetic neuropathy. Diabetes  1997; 46(Suppl. 2): S38-42.
[http://dx.doi.org/10.2337/diab.46.2.S38] [PMID: 9285497] 
[359] 
Ametov AS, Barinov A, Dyck PJ, et al. The sensory symptoms of diabetic polyneuropathy are improved with alpha-lipoic acid: the SYDNEY trial. Diabetes Care  2003; 26(3): 770-6.
[http://dx.doi.org/10.2337/diacare.26.3.770] [PMID: 12610036] 
[360] 
Ziegler D, Nowak H, Kempler P, Vargha P, Low PA. Treatment of symptomatic diabetic polyneuropathy with the antioxidant alpha-lipoic acid: a meta-analysis. Diabet Med  2004; 21(2): 114-21.
[http://dx.doi.org/10.1111/j.1464-5491.2004.01109.x] [PMID: 14984445] 
[361] 
Mijnhout GS, Kollen BJ, Alkhalaf A, Kleefstra N, Bilo HJ. Alpha lipoic Acid for symptomatic peripheral neuropathy in patients with diabetes: a meta-analysis of randomized controlled trials. Int J Endocrinol  2012; 2012: 456279.
[http://dx.doi.org/10.1155/2012/456279] [PMID: 22331979] 
[362] 
Ziegler D, Ametov A, Barinov A, et al. Oral treatment with alpha-lipoic acid improves symptomatic diabetic polyneuropathy: the SYDNEY 2 trial. Diabetes Care  2006; 29(11): 2365-70.
[http://dx.doi.org/10.2337/dc06-1216] [PMID: 17065669] 
[363] 
Ziegler D, Hanefeld M, Ruhnau KJ, et al. Treatment of symptomatic diabetic polyneuropathy with the antioxidant alpha-lipoic acid: a 7-month multicenter randomized controlled trial (ALADIN III Study). ALADIN III Study Group. Alpha-Lipoic Acid in Diabetic Neuropathy. Diabetes Care  1999; 22(8): 1296-301.
[http://dx.doi.org/10.2337/diacare.22.8.1296] [PMID: 10480774] 
[364] 
Ziegler D, Hanefeld M, Ruhnau KJ, et al. Treatment of symptomatic diabetic peripheral neuropathy with the anti-oxidant alpha-lipoic acid. A 3-week multicentre randomized controlled trial (ALADIN Study). Diabetologia  1995; 38(12): 1425-33.
[http://dx.doi.org/10.1007/BF00400603] [PMID: 8786016] 
[365] 
Ziegler D, Low PA, Litchy WJ, et al. Efficacy and safety of antioxidant treatment with α-lipoic acid over 4 years in diabetic polyneuropathy: the NATHAN 1 trial. Diabetes Care  2011; 34(9): 2054-60.
[http://dx.doi.org/10.2337/dc11-0503] [PMID: 21775755] 
[366] 
Boulton AJ, Kempler P, Ametov A, Ziegler D. Whither pathogenetic treatments for diabetic polyneuropathy? Diabetes Metab Res Rev  2013; 29(5): 327-33.
[http://dx.doi.org/10.1002/dmrr.2397] [PMID: 23381942] 
[367] 
Bril V, Hirose T, Tomioka S, Buchanan R, Group RS. Ranirestat for the management of diabetic sensorimotor polyneuropathy. Diabetes Care  2009; 32(7): 1256-60.
[http://dx.doi.org/10.2337/dc08-2110] [PMID: 19366965] 
[368] 
Hotta N, Akanuma Y, Kawamori R, et al. Long-term clinical effects of epalrestat, an aldose reductase inhibitor, on diabetic peripheral neuropathy: the 3-year, multicenter, comparative Aldose Reductase Inhibitor-Diabetes Complications Trial. Diabetes Care  2006; 29(7): 1538-44.
[http://dx.doi.org/10.2337/dc05-2370] [PMID: 16801576] 
[369] 
Hammes HP, Du X, Edelstein D, et al. Benfotiamine blocks three major pathways of hyperglycemic damage and prevents experimental diabetic retinopathy. Nat Med  2003; 9(3): 294-9.
[http://dx.doi.org/10.1038/nm834] [PMID: 12592403] 
[370] 
Stracke H, Gaus W, Achenbach U, Federlin K, Bretzel RG. Benfotiamine in diabetic polyneuropathy (BENDIP): results of a randomised, double blind, placebo-controlled clinical study. Exp Clin Endocrinol Diabetes  2008; 116(10): 600-5.
[http://dx.doi.org/10.1055/s-2008-1065351] [PMID: 18473286] 
[371] 
Bönhof GJ, Herder C, Strom A, Papanas N, Roden M, Ziegler D. Emerging biomarkers, tools, and treatments for diabetic polyneuropathy. Endocr Rev  2019; 40(1): 153-92.
[http://dx.doi.org/10.1210/er.2018-00107] [PMID: 30256929] 
[372] 
Ziegler D, Movsesyan L, Mankovsky B, Gurieva I, Abylaiuly Z, Strokov I. Treatment of symptomatic polyneuropathy with actovegin in type 2 diabetic patients. Diabetes Care  2009; 32(8): 1479-84.
[http://dx.doi.org/10.2337/dc09-0545] [PMID: 19470838] 
[373] 
Apfel SC, Schwartz S, Adornato BT, et al. Efficacy and safety of recombinant human nerve growth factor in patients with diabetic polyneuropathy: A randomized controlled trial. rhNGF Clinical Investigator Group. JAMA  2000; 284(17): 2215-21.
[http://dx.doi.org/10.1001/jama.284.17.2215] [PMID: 11056593] 
[374] 
Bansal D, Badhan Y, Gudala K, Schifano F. Ruboxistaurin for the treatment of diabetic peripheral neuropathy: a systematic review of randomized clinical trials. Diabetes Metab J  2013; 37(5): 375-84.
[http://dx.doi.org/10.4093/dmj.2013.37.5.375] [PMID: 24199167] 
[375] 
Wahren J, Foyt H, Daniels M, Arezzo JC. Long-acting c-peptide and neuropathy in type 1 diabetes: A 12-month clinical trial. Diabetes Care  2016; 39(4): 596-602.
[http://dx.doi.org/10.2337/dc15-2068] [PMID: 26884473] 
[376] 
Akahori H, Takamura T, Hayakawa T, Ando H, Yamashita H, Kobayashi K. Prostaglandin E1 in lipid microspheres ameliorates diabetic peripheral neuropathy: clinical usefulness of Semmes-Weinstein monofilaments for evaluating diabetic sensory abnormality. Diabetes Res Clin Pract  2004; 64(3): 153-9.
[http://dx.doi.org/10.1016/j.diabres.2003.10.012] [PMID: 15126001] 
[377] 
Holbech JV, Bach FW, Finnerup NB, Brøsen K, Jensen TS, Sindrup SH. Imipramine and pregabalin combination for painful polyneuropathy: a randomized controlled trial. Pain  2015; 156(5): 958-66.
[http://dx.doi.org/10.1097/j.pain.0000000000000143] [PMID: 25719617] 
[378] 
Gilron I, Tu D, Holden RR, Jackson AC, DuMerton-Shore D. Combination of morphine with nortriptyline for neuropathic pain. Pain  2015; 156(8): 1440-8.
[http://dx.doi.org/10.1097/j.pain.0000000000000149] [PMID: 25749306] 
[379] 
Shillo P, Selvarajah D, Greig M, et al. Reduced vitamin D levels in painful diabetic peripheral neuropathy. Diabet Med  2019; 36(1): 44-51.
[http://dx.doi.org/10.1111/dme.13798] [PMID: 30102801] 
[380] 
Alam U, Petropoulos IN, Ponirakis G, et al. Vitamin D deficiency is associated with painful diabetic neuropathy. Diabetes Metab Res Rev  2021; 37(1): e3361.
[http://dx.doi.org/10.1002/dmrr.3361] [PMID: 32506740] 
[381] 
Basit A, Basit KA, Fawwad A, et al. Vitamin D for the treatment of painful diabetic neuropathy. BMJ Open Diabetes Res Care  2016; 4(1): e000148.
[http://dx.doi.org/10.1136/bmjdrc-2015-000148] [PMID: 27026808] 
[382] 
Alam U, Fawwad A, Shaheen F, Tahir B, Basit A, Malik RA. Improvement in neuropathy specific quality of life in patients with diabetes after vitamin d supplementation. J Diabetes Res  2017; 2017: 7928083.
[http://dx.doi.org/10.1155/2017/7928083] [PMID: 29445752] 
[383] 
Shehab D, Al-Jarallah K, Abdella N, Mojiminiyi OA, Al Mohamedy H. Prospective evaluation of the effect of short-term oral vitamin d supplementation on peripheral neuropathy in type 2 diabetes mellitus. Med Princ Pract  2015; 24(3): 250-6.
[http://dx.doi.org/10.1159/000375304] [PMID: 25720672] 
[384] 
Liu Y, Luo B, Han F, et al. Erythropoietin-derived nonerythropoietic peptide ameliorates experimental autoimmune neuritis by inflammation suppression and tissue protection. PLoS One  2014; 9(3): e90942.
[http://dx.doi.org/10.1371/journal.pone.0090942] [PMID: 24603865] 
[385] 
Brines M, Dunne AN, van Velzen M, et al. ARA 290, a nonerythropoietic peptide engineered from erythropoietin, improves metabolic control and neuropathic symptoms in patients with type 2 diabetes. Mol Med  2015; 20: 658-66.
[http://dx.doi.org/10.2119/molmed.2014.00215] [PMID: 25387363] 
[386] 
Emery EC, Luiz AP, Wood JN. Nav1.7 and other voltage-gated sodium channels as drug targets for pain relief. Expert Opin Ther Targets  2016; 20(8): 975-83.
[http://dx.doi.org/10.1517/14728222.2016.1162295] [PMID: 26941184] 
[387] 
Lee JH, Park CK, Chen G, et al. A monoclonal antibody that targets a NaV1.7 channel voltage sensor for pain and itch relief. Cell  2014; 157(6): 1393-404.
[http://dx.doi.org/10.1016/j.cell.2014.03.064] [PMID: 24856969] 
[388] 
McDonnell A, Collins S, Ali Z, et al. Efficacy of the Nav1.7 blocker PF-05089771 in a randomised, placebo-controlled, double-blind clinical study in subjects with painful diabetic peripheral neuropathy. Pain  2018; 159(8): 1465-76.
[http://dx.doi.org/10.1097/j.pain.0000000000001227] [PMID: 29578944] 
[389] 
Calandre EP, Morillas-Arques P, Molina-Barea R, Rodriguez-Lopez CM, Rico-Villademoros F. Trazodone plus pregabalin combination in the treatment of fibromyalgia: a two-phase, 24-week, open-label uncontrolled study. BMC Musculoskelet Disord  2011; 12: 95.
[http://dx.doi.org/10.1186/1471-2474-12-95] [PMID: 21575194] 
[390] 
Tesfaye S. PL37: a new hope in the treatment of painful diabetic neuropathy? Pain Manag (Lond)  2016; 6(2): 129-32.
[http://dx.doi.org/10.2217/pmt.15.68] [PMID: 26984197] 
[391] 
Thibault K, Elisabeth B, Sophie D, Claude FZ, Bernard R, Bernard C. Antinociceptive and anti-allodynic effects of oral PL37, a complete inhibitor of enkephalin-catabolizing enzymes, in a rat model of peripheral neuropathic pain induced by vincristine. Eur J Pharmacol  2008; 600(1-3): 71-7.
[http://dx.doi.org/10.1016/j.ejphar.2008.10.004] [PMID: 18938155] 
[392] 
Bernier LP, Ase AR, Séguéla P. P2X receptor channels in chronic pain pathways. Br J Pharmacol  2018; 175(12): 2219-30.
[http://dx.doi.org/10.1111/bph.13957] [PMID: 28728214] 
[393] 
Rao S, Liu S, Zou L, et al. The effect of sinomenine in diabetic neuropathic pain mediated by the P2X3 receptor in dorsal root ganglia. Purinergic Signal  2017; 13(2): 227-35.
[http://dx.doi.org/10.1007/s11302-016-9554-z] [PMID: 28054206] 
[394] 
Yang R, Li L, Yuan H, et al. Quercetin relieved diabetic neuropathic pain by inhibiting upregulated P2X4 receptor in dorsal root ganglia. J Cell Physiol  2019; 234(3): 2756-64.
[http://dx.doi.org/10.1002/jcp.27091] [PMID: 30145789] 
[395] 
Guan S, Shen Y, Ge H, et al. Dihydromyricetin alleviates diabetic neuropathic pain and depression comorbidity symptoms by inhibiting p2x7 receptor. Front Psychiatry  2019; 10: 770.
[http://dx.doi.org/10.3389/fpsyt.2019.00770] [PMID: 31681052] 
[396] 
Irizarry MC, Webb DJ, Ali Z, et al. Predictors of placebo response in pooled lamotrigine neuropathic pain clinical trials. Clin J Pain  2009; 25(6): 469-76.
[http://dx.doi.org/10.1097/AJP.0b013e31819ddded] [PMID: 19542793] 
[397] 
Farrar JT, Troxel AB, Haynes K, et al. Effect of variability in the 7-day baseline pain diary on the assay sensitivity of neuropathic pain randomized clinical trials: an ACTTION study. Pain  2014; 155(8): 1622-31.
[http://dx.doi.org/10.1016/j.pain.2014.05.009] [PMID: 24831421] 
[398] 
Freeman R, Emir B, Parsons B. Predictors of placebo response in peripheral neuropathic pain: insights from pregabalin clinical trials. J Pain Res  2015; 8: 257-68.
[PMID: 26082659] 
[399] 
Finnerup NB, Haroutounian S, Baron R, et al. Neuropathic pain clinical trials: factors associated with decreases in estimated drug efficacy. Pain  2018; 159(11): 2339-46.
[http://dx.doi.org/10.1097/j.pain.0000000000001340] [PMID: 30015707] 
[400] 
Finnerup NB, Haroutounian S, Kamerman P, et al. Neuropathic pain: an updated grading system for research and clinical practice. Pain  2016; 157(8): 1599-606.
[http://dx.doi.org/10.1097/j.pain.0000000000000492] [PMID: 27115670] 
[401] 
Haanpää M, Attal N, Backonja M, et al. NeuPSIG guidelines on neuropathic pain assessment. Pain  2011; 152(1): 14-27.
[http://dx.doi.org/10.1016/j.pain.2010.07.031] [PMID: 20851519] 
[402] 
Dworkin RH, Turk DC, Peirce-Sandner S, et al. Considerations for improving assay sensitivity in chronic pain clinical trials: IMMPACT recommendations. Pain  2012; 153(6): 1148-58.
[http://dx.doi.org/10.1016/j.pain.2012.03.003] [PMID: 22494920] 
[403] 
Gewandter JS, Dworkin RH, Turk DC, et al. Improving study conduct and data quality in clinical trials of chronic pain treatments: Immpact recommendations. J Pain  2020; 21(9-10): 931-42.
[PMID: 31843583] 
[404] 
Smith SM, Dworkin RH, Turk DC, et al. Interpretation of chronic pain clinical trial outcomes: IMMPACT recommended considerations. Pain  2020; 161(11): 2446-61.
[http://dx.doi.org/10.1097/j.pain.0000000000001952] [PMID: 32520773] 
[405] 
Bouhassira D, Attal N, Fermanian J, et al. Development and validation of the Neuropathic Pain Symptom Inventory. Pain  2004; 108(3): 248-57.
[http://dx.doi.org/10.1016/j.pain.2003.12.024] [PMID: 15030944] 
[406] 
Rolke R, Baron R, Maier C, et al. Quantitative sensory testing in the German Research Network on Neuropathic Pain (DFNS): standardized protocol and reference values. Pain  2006; 123(3): 231-43.
[http://dx.doi.org/10.1016/j.pain.2006.01.041] [PMID: 16697110] 
[407] 
Baron R, Tölle TR, Gockel U, Brosz M, Freynhagen R. A cross-sectional cohort survey in 2100 patients with painful diabetic neuropathy and postherpetic neuralgia: Differences in demographic data and sensory symptoms. Pain  2009; 146(1-2): 34-40.
[http://dx.doi.org/10.1016/j.pain.2009.06.001] [PMID: 19592166] 
[408] 
Freeman R, Baron R, Bouhassira D, Cabrera J, Emir B. Sensory profiles of patients with neuropathic pain based on the neuropathic pain symptoms and signs. Pain  2014; 155(2): 367-76.
[http://dx.doi.org/10.1016/j.pain.2013.10.023] [PMID: 24472518] 
[409] 
Baron R, Maier C, Attal N, et al. Peripheral neuropathic pain: a mechanism-related organizing principle based on sensory profiles. Pain  2017; 158(2): 261-72.
[http://dx.doi.org/10.1097/j.pain.0000000000000753] [PMID: 27893485] 
[410] 
Bouhassira D, Wilhelm S, Schacht A, et al. Neuropathic pain phenotyping as a predictor of treatment response in painful diabetic neuropathy: data from the randomized, double-blind, COMBO-DN study. Pain  2014; 155(10): 2171-9.
[http://dx.doi.org/10.1016/j.pain.2014.08.020] [PMID: 25168665] 
[411] 
Sansone RA, Sansone LA. Serotonin norepinephrine reuptake inhibitors: a pharmacological comparison. Innov Clin Neurosci  2014; 11(3-4): 37-42.
[PMID: 24800132] 
[412] 
Hunziker ME, Suehs BT, Bettinger TL, Crismon ML. Duloxetine hydrochloride: a new dual-acting medication for the treatment of major depressive disorder. Clin Ther  2005; 27(8): 1126-43.
[http://dx.doi.org/10.1016/j.clinthera.2005.08.010] [PMID: 16199241] 
[413] 
Serra J. Microneurography: towards a biomarker of spontaneous pain. Pain  2012; 153(10): 1989-90.
[http://dx.doi.org/10.1016/j.pain.2012.07.008] [PMID: 22820023] 
[414] 
Kleggetveit IP, Namer B, Schmidt R, et al. High spontaneous activity of C-nociceptors in painful polyneuropathy. Pain  2012; 153(10): 2040-7.
[http://dx.doi.org/10.1016/j.pain.2012.05.017] [PMID: 22986070] 
[415] 
Sun W, Miao B, Wang XC, et al. Reduced conduction failure of the main axon of polymodal nociceptive C-fibres contributes to painful diabetic neuropathy in rats. Brain  2012; 135(Pt 2): 359-75.
[http://dx.doi.org/10.1093/brain/awr345] [PMID: 22271663] 
[416] 
Serra J, Duan WR, Locke C, Solà R, Liu W, Nothaft W. Effects of a T-type calcium channel blocker, ABT-639, on spontaneous activity in C-nociceptors in patients with painful diabetic neuropathy: a randomized controlled trial. Pain  2015; 156(11): 2175-83.
[http://dx.doi.org/10.1097/j.pain.0000000000000249] [PMID: 26035253] 
[417] 
Demant DT, Lund K, Vollert J, et al. The effect of oxcarbazepine in peripheral neuropathic pain depends on pain phenotype: a randomised, double-blind, placebo-controlled phenotype-stratified study. Pain  2014; 155(11): 2263-73.
[http://dx.doi.org/10.1016/j.pain.2014.08.014] [PMID: 25139589] 
[418] 
de Greef BTA, Hoeijmakers JGJ, Geerts M, et al. Lacosamide in patients with Nav1.7 mutations-related small fibre neuropathy: a randomized controlled trial. Brain  2019; 142(2): 263-75.
[http://dx.doi.org/10.1093/brain/awy329] [PMID: 30649227] 
[419] 
Edwards RR, Dworkin RH, Turk DC, et al. Patient phenotyping in clinical trials of chronic pain treatments: IMMPACT recommendations. Pain  2016; 157(9): 1851-71.
[http://dx.doi.org/10.1097/j.pain.0000000000000602] [PMID: 27152687] 
[420] 
Smith SM, Dworkin RH, Turk DC, et al. The potential role of sensory testing, skin biopsy, and functional brain imaging as biomarkers in chronic pain clinical trials: IMMPACT considerations. J Pain  2017; 18(7): 757-77.
[http://dx.doi.org/10.1016/j.jpain.2017.02.429] [PMID: 28254585] 
[421] 
Yang H, Sloan G, Ye Y, et al. New perspective in diabetic neuropathy: From the periphery to the brain, a call for early detection, and precision medicine. Front Endocrinol (Lausanne)  2020; 10: 929.
[http://dx.doi.org/10.3389/fendo.2019.00929] [PMID: 32010062] 
Rights & Permissions Print Cite
Article Metrics
54
1
Journal Information
For Authors
For Editors
For Reviewers
Explore Articles
Open Access
Open Access Articles
For Visitors
DOI https://dx.doi.org/10.2174/1573399817666210707112413	Print ISSN 1573-3998
Publisher Name Bentham Science Publisher	Online ISSN 1875-6417
Current Diabetes Reviews

The Treatment of Painful Diabetic Neuropathy

Abstract Play Pause

Related Journals

Related Books

Related Articles

Abstract
